<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71595</article-id><article-id pub-id-type="doi">10.7554/eLife.71595</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>SLC1A5 provides glutamine and asparagine necessary for bone development in mice</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-243643"><name><surname>Sharma</surname><given-names>Deepika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243783"><name><surname>Yu</surname><given-names>Yilin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243782"><name><surname>Shen</surname><given-names>Leyao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243784"><name><surname>Zhang</surname><given-names>Guo-Fang</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-228116"><name><surname>Karner</surname><given-names>Courtney M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0387-4486</contrib-id><email>courtney.karner@utsouthwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Department of Orthopaedic Surgery, Duke University School of Medicine</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Internal Medicine, University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Sarah W. Stedman Nutrition and Metabolism Center &amp; Duke Molecular Physiology Institute, Duke University Medical Center</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Medicine, Duke University School of Medicine</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Charles and Jane Pak Center for Mineral Metabolism and Clinical Research. University of Texas Southwestern Medical Center at Dallas</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schipani</surname><given-names>Ernestina</given-names></name><role>Reviewing Editor</role><aff><institution>University of Pennsylvania</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Senior Editor</role><aff><institution>Medical College of Georgia at Augusta University</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>14</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e71595</elocation-id><history><date date-type="received" iso-8601-date="2021-06-24"><day>24</day><month>06</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-12"><day>12</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Sharma et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Sharma et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-71595-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-71595-figures-v2.pdf"/><abstract><p>Osteoblast differentiation is sequentially characterized by high rates of proliferation followed by increased protein and matrix synthesis, processes that require substantial amino acid acquisition and production. How osteoblasts obtain or maintain intracellular amino acid production is poorly understood. Here, we identify SLC1A5 as a critical amino acid transporter during bone development. Using a genetic and metabolomic approach, we show SLC1A5 acts cell autonomously to regulate protein synthesis and osteoblast differentiation. SLC1A5 provides both glutamine and asparagine which are essential for osteoblast differentiation. Mechanistically, glutamine and to a lesser extent asparagine support amino acid biosynthesis. Thus, osteoblasts depend on <italic>Slc1a5</italic> to provide glutamine and asparagine, which are subsequently used to produce non-essential amino acids and support osteoblast differentiation and bone development.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>asparagine</kwd><kwd>osteoblast</kwd><kwd>glutamine</kwd><kwd>bone</kwd><kwd>Slc1a5</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>AR076325</award-id><principal-award-recipient><name><surname>Karner</surname><given-names>Courtney M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>AR071967</award-id><principal-award-recipient><name><surname>Karner</surname><given-names>Courtney M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Osteoblasts utilize an elegant mechanism by which they obtain and subsequently synthesize the requisite amino acids to support osteoblast differentiation and bone formation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Osteoblasts are secretory cells responsible for producing and secreting the Collagen Type one rich extracellular bone matrix. Osteoblasts differentiate from mesenchymal progenitors in a well-coordinated temporal sequence regulated by the transcription factors RUNX2 and OSX (encoded by <italic>Sp7</italic>) (<xref ref-type="bibr" rid="bib33">Nakashima et al., 2002</xref>; <xref ref-type="bibr" rid="bib37">Otto et al., 1997</xref>). Osteoblast progenitors are proliferative before undergoing terminal differentiation into postmitotic Collagen Type 1 (COL1A1) matrix producing osteoblasts (<xref ref-type="bibr" rid="bib43">Quarles et al., 1992</xref>; <xref ref-type="bibr" rid="bib40">Pardee et al., 1978</xref>; <xref ref-type="bibr" rid="bib56">Tonna and Cronkite, 1961</xref>; <xref ref-type="bibr" rid="bib53">Stein et al., 1990</xref>; <xref ref-type="bibr" rid="bib54">Stein and Lian, 1993</xref>). Both proliferation and matrix production are biosynthetically demanding and burden osteoblasts with enhanced metabolic demands. For example, proliferation requires cells to increase nutrient and amino acid acquisition to generate the biomass necessary to duplicate cell mass for division. Likewise, matrix production places similar demands upon osteoblasts. Thus, bone formation is associated with increased synthetic demands due to osteoblast proliferation, differentiation, and bone matrix production (<xref ref-type="bibr" rid="bib16">Guntur et al., 2014</xref>; <xref ref-type="bibr" rid="bib29">Lee et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Karner and Long, 2018</xref>; <xref ref-type="bibr" rid="bib46">Riddle and Clemens, 2017</xref>).</p><p>These enhanced synthetic demands are predicted to require a constant supply of amino acids to sustain both proliferation and bone matrix production. Cells can obtain amino acids via uptake from the extracellular milieu or from de novo synthesis from glucose or other amino acids (<xref ref-type="bibr" rid="bib25">Karner and Long, 2018</xref>; <xref ref-type="bibr" rid="bib13">Flanagan and Nichols, 1964</xref>; <xref ref-type="bibr" rid="bib1">Adamson and Ingbar, 1967</xref>; <xref ref-type="bibr" rid="bib11">Finerman and Rosenberg, 1966</xref>; <xref ref-type="bibr" rid="bib65">Yee, 1988</xref>; <xref ref-type="bibr" rid="bib39">Palm and Thompson, 2017</xref>). In osteoblasts, amino acid consumption is known to be transcriptionally regulated (<xref ref-type="bibr" rid="bib10">Elefteriou et al., 2006</xref>; <xref ref-type="bibr" rid="bib44">Rached et al., 2010</xref>) and rapidly increases during differentiation and in response to osteoinductive signals (<xref ref-type="bibr" rid="bib23">Karner et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Shen et al., 2021</xref>; <xref ref-type="bibr" rid="bib66">Yu et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Hahn et al., 1969</xref>; <xref ref-type="bibr" rid="bib42">Phang and Downing, 1973</xref>). Importantly, genetic mutations that limit amino acid uptake are associated with decreased proliferative capacity and reduced bone formation (<xref ref-type="bibr" rid="bib10">Elefteriou et al., 2006</xref>; <xref ref-type="bibr" rid="bib44">Rached et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Hu et al., 2020</xref>). Despite this, little is known about how osteoblasts obtain the amino acids necessary to promote robust proliferation and bone matrix synthesis.</p><p>The regulation of amino acid supply is an important regulatory node that is frequently upregulated to support proliferation and biosynthesis in many pathological conditions (<xref ref-type="bibr" rid="bib14">Garcia-Bermudez et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">Jones et al., 2019</xref>; <xref ref-type="bibr" rid="bib2">Bhutia et al., 2015</xref>; <xref ref-type="bibr" rid="bib5">BrÃ¶er et al., 2016</xref>). Amino acid uptake is controlled by a diverse array of membrane-bound transport proteins that transport amino acids into and out of the cell. Once inside the cell, amino acids have diverse fates. For example, amino acids may contribute directly to protein synthesis, facilitate signaling or be metabolized to generate ATP or other intermediate metabolites including other amino acids (<xref ref-type="bibr" rid="bib7">DeBerardinis et al., 2007</xref>; <xref ref-type="bibr" rid="bib15">Green et al., 2016</xref>; <xref ref-type="bibr" rid="bib60">Wang et al., 2009</xref>; <xref ref-type="bibr" rid="bib24">Karner and Long, 2017</xref>). How osteoblasts obtain or utilize amino acids is not well understood. We recently identified Alanine, Serine, Cysteine transporter 2 (ASCT2, denoted herein as SLC1A5, encoded by <italic>Slc1a5</italic>) as a potential regulator of amino acid supply in osteoblast progenitors (<xref ref-type="bibr" rid="bib50">Shen et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Hu et al., 2020</xref>). SLC1A5 is a Na<sup>+</sup>-dependent neutral amino acid exchanger that can transport glutamine, alanine, serine, asparagine, and threonine (<xref ref-type="bibr" rid="bib4">BrÃ¶er et al., 1999</xref>; <xref ref-type="bibr" rid="bib49">Scopelliti et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Utsunomiya-Tate et al., 1996</xref>; <xref ref-type="bibr" rid="bib34">Nakaya et al., 2014</xref>; <xref ref-type="bibr" rid="bib62">Wu et al., 2021</xref>). In cancer cells, <italic>Slc1a5</italic> upregulation is associated with metabolic reprograming and is necessary for increased proliferation and biosynthesis (<xref ref-type="bibr" rid="bib5">BrÃ¶er et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Ren et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">van Geldermalsen et al., 2016</xref>; <xref ref-type="bibr" rid="bib61">Wang et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Schulte et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Hassanein et al., 2013</xref>). In comparison, little is known about the role of SLC1A5-dependent amino acid uptake during bone development.</p><p>Here, we define the role of amino acid uptake through <italic>Slc1a5</italic> during bone development and homeostasis. Using a genetic and metabolic approach, we demonstrate <italic>Slc1a5</italic> is required for osteoblast proliferation, differentiation and bone matrix production. Mechanistically, SLC1A5 provides glutamine and asparagine to maintain intracellular amino acid homeostasis in osteoblasts. Collectively, these data highlight the previously unknown role for <italic>Slc1a5</italic> in osteoblasts regulating differentiation and bone development.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Slc1a5</italic> is required for bone development</title><p>We previously identified <italic>Slc1a5</italic> as a potential regulator of proliferation and WNT induced osteoblast differentiation in stromal cells (<xref ref-type="bibr" rid="bib50">Shen et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Hu et al., 2020</xref>). To understand if <italic>Slc1a5</italic> functions in osteoblasts, we first characterized <italic>Slc1a5</italic> expression during osteoblast differentiation. <italic>Slc1a5</italic> is highly expressed in both naive calvarial cells and bone marrow stromal cells and significantly increases during osteoblast differentiation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). To determine if <italic>Slc1a5</italic> is required for osteoblast differentiation, we first utilized a CRISPR/Cas9 approach to knock out <italic>Slc1a5</italic> in cultured calvarial cells (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1A</xref>). Western blot analyses confirmed this approach effectively ablated SLC1A5 protein (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1B</xref>). <italic>Slc1a5</italic> targeting did not affect early osteoblast differentiation but did prevent the induction of the mature osteoblast genes <italic>Ibsp</italic> and <italic>Bglap</italic> and prevented matrix mineralization in primary calvarial cells (<xref ref-type="fig" rid="fig1">Figure 1BâC</xref>). To determine if <italic>Slc1a5</italic>-dependent amino acid uptake is important for osteoblast differentiation in vivo, we generated a conditional (floxed) <italic>Slc1a5</italic> allele (<italic>Slc1a5<sup>fl</sup></italic>) using homologous recombination (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1C</xref>). These mice were crossed with the <italic>Sp7tTA;tetOeGFP/Cre</italic> deleter mouse (denoted hereafter as <italic>Sp7Cre</italic>) that expresses GFP and Cre recombinase under the control of the <italic>Sp7</italic> promoter to generate mice lacking <italic>Slc1a5</italic> in committed osteoblast progenitors (<xref ref-type="bibr" rid="bib47">Rodda and McMahon, 2006</xref>). Western blot analysis confirmed the specific ablation of SLC1A5 in bones isolated from <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1D</xref>). <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice were characterized by delayed endochondral and intramembranous ossification evident at both embryonic (E) day E14.5 and E15.5 (<xref ref-type="fig" rid="fig1">Figure 1DâEâ</xref>). In addition to delayed mineralization, <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice had reduced size of various skeletal elements (exemplified by the humerus, <xref ref-type="fig" rid="fig1">Figure 1F and J</xref>) relative to <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> littermate controls (<xref ref-type="fig" rid="fig1">Figure 1FâG and JâK</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1E-L</xref>). By E16.5 the extent of mineralization was no longer significantly different although the overall length of individual skeletal elements was significantly different from <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> littermate controls (<xref ref-type="fig" rid="fig1">Figure 1LâO</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1M-P</xref>). At birth, neither matrix mineralization or nor element length were significantly different suggesting there is a transient delay in endochondral ossification (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1Q-X</xref>). Conversely, <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice are characterized by impaired intramembranous ossification at all stages evaluated (<xref ref-type="fig" rid="fig1">Figure 1DâEâ, LâM and PâQ</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1Q-R</xref>). At birth, <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> calvariae had increased porosity (1.0 Â± 0.2 vs 2.3 Â± 0.2 in <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> respectively, p &lt; 0.05), increased suture width (1.0 Â± 0.2 mm vs 1.4 Â± 0.3 in <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> respectively, p &lt; 0.05) and significantly less bone volume (0.7% Â± 0.02% vs 0.6 Â± 0.05% in <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> respectively, p &lt; 0.05) as measured by micro-computed tomography (ÂµCT) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). At 2-months of age, <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice presented with less bone mass, increased suture width and altered suture morphology (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2</xref>). Von Kossa staining of histological sections confirmed the reduction in mineralized bone matrix in newborn <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> calvariae (<xref ref-type="fig" rid="fig1">Figure 1TâU</xref>). Thus, <italic>Slc1a5</italic> expression in osteoprogenitors is essential for bone development.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Slc1a5 is required for bone development in mice.</title><p>(<bold>A</bold>) qRT-PCR analyses of gene expression in calvarial osteoblasts (cOB) cultured for 7 days in growth or osteogenic media. (<bold>BâC</bold>) qRT-PCR analyses (<bold>B</bold>) or functional assays (<bold>C</bold>) of the effect of <italic>Slc1a5</italic> deletion on osteoblast differentiation in cOB cultured for 7 days in osteogenic media. (<bold>DâO</bold>) Skeletal preparations of <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice at E14.5 (n = 5), E15.5 (N = 8) and E16.5 (N = 5). Arrows denote reduced mineralization. Isolated humeri shown in (<bold>F</bold>), (<bold>J</bold>) and (<bold>N</bold>). Blue dotted lines denotes the control overall humerus length. Red dotted lines denote control mineralized area. Images quantified in (<bold>G, K and O). (PâS</bold>) A representative skeletal preparation (<bold>PâQ</bold>) or (<bold>RâS</bold>) Representative Micro-computed tomography (Î¼CT) (N = 6) used to quantify BV/TV(%) and (<bold>TâU</bold>) von Kossa staining on <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> (N = 4) knockout mice at P0. Error bars depict SD. * p â¤ 0.05, ** p â¤ 0.005, *** p â¤ 0.0005, **** p â¤ 0.00005, by an unpaired two-tailed Studentâs <italic>t</italic>-test.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1âsource data 1.</label><caption><title>Contains numerical source data for <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>Slc1a5 ablation decreases bone development.</title><p>(<bold>A</bold>) <italic>Slc1a5</italic> Crispr targeting strategy(<bold>B</bold>) Western Blot analyses of the effect of <italic>Slc1a5</italic> targeting ASCT2 normalized to Î±-tubulin. sgRNAs targeting luciferase and mCherry were used as a negative control. Fold changeÂ± SD for <italic>sgSlc1a5</italic> over <italic>sgLuc</italic> in three independent experiments. * p â¤ 0.05 by an unpaired two-tailed Studentâs <italic>t</italic>-test. (<bold>C</bold>) <italic>Slc1a5<sup>fl</sup></italic> targeting strategy. (<bold>D</bold>) Western Blot analyses of SLC1A5 (ASCT2) expression in protein isolated from Muscle, Bone and Bone marrow from <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice. (<bold>EâX</bold>) Skeletal preparations of <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> hindlimbs at E14.5 (n = 5), E15.5 (N = 8), E16.5 (N = 5) and (<bold>p0</bold>). Images quantified in (<bold>G, H, K,L,O, P,U and X</bold>).</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1âfigure supplement 1âsource data 1.</label><caption><title>Contains numerical and uncropped western blot source data for <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 2.</label><caption><title>Skull phenotype at 2 months of age in <italic>Sp7Cre;Slc1a5fl/fl</italic> mice.</title><p>(<bold>AâB</bold>) Representative X-Ray, (<bold>CâD</bold>) ÂµCT image of a whole calvarium from 2-month-old <italic>Sp7Cre;Slc1a5fl/+</italic> or <italic>Sp7Cre;Slc1a5fl/fl</italic> littermates.</p><p>(<bold>EâF</bold>) H&amp;E staining and cartoon depiction of section through the coronal suture (level of section indicated by the dotted red line in (<bold>C,D</bold>)) showing altered suture morphology.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig1-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title><italic>Slc1a5</italic> is required for osteoblast differentiation and proliferation</title><p>To determine how <italic>Slc1a5</italic> regulates bone development, we first characterized the cellular effects of <italic>Slc1a5</italic> ablation on osteoblasts. Because we observed a consistent skull phenotype at all stages and <italic>Sp7Cre</italic> is expressed in both osteoblasts and hypertrophic chondrocytes in the developing limb (<xref ref-type="bibr" rid="bib47">Rodda and McMahon, 2006</xref>), we focused our analyses on the skull which is formed by intramembranous ossification and does not involve a cartilaginous intermediate (<xref ref-type="bibr" rid="bib36">Ornitz and Marie, 2002</xref>). Von Kossa staining confirmed there was delayed mineralization in <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> calvariae at E15.5 (<xref ref-type="fig" rid="fig2">Figure 2AâD</xref>). This was not due to changes in the number of osteoblast progenitors as we observed no significant difference in the number of <italic>Sp7<sup>GFP</sup></italic> expressing osteoblast progenitors per bone area in <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice compared to <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> wild type littermates (75.3% Â± 11.6% vs 64.7Â±9.5 % in <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/f</sup></italic> animals, respectively) (<xref ref-type="fig" rid="fig2">Figure 2EâF</xref>). However, we did observe a significant reduction in the proportion of Sp7<sup>GFP</sup> cells that were positive for proliferating cell nuclear antigen (PCNA) (25.9% Â± 4.6% vs 15.6Â±2.9 % in <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> or <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> respectively, p &lt; 0.05) (<xref ref-type="fig" rid="fig2">Figure 2GâJ</xref>) suggesting <italic>Slc1a5</italic> is required for proliferation of <italic>Sp7</italic> expressing osteoblast progenitors. We next evaluated osteoblast differentiation using in situ hybridization. We did not observe significant differences in the expression of early osteoblast genes including alkaline phosphatase (Alpl, as determined by in situ staining) or <italic>Col1a1</italic> (<xref ref-type="fig" rid="fig2">Figure 2KâN</xref>). Conversely, <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> animals had reduced expression of the osteoblast differentiation genes <italic>Spp1</italic> and <italic>Ibsp</italic> at both E15.5 and postnatal (P) day 0 (P0) (<xref ref-type="fig" rid="fig2">Figure 2OâT</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1A-B</xref>). Similarly, the mature osteoblast gene <italic>Bglap</italic> was highly reduced at P0 in <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> compared to <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> littermates (<xref ref-type="fig" rid="fig2">Figure 2UâV</xref>). Consistent with these observations, primary calvarial cells isolated from <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice incorporated less EdU and were characterized by reduced osteoblast differentiation and matrix mineralization in vitro (<xref ref-type="fig" rid="fig2">Figure 2WâX</xref>). This is likely a direct effect of loss of <italic>Slc1a5</italic> activity as acute SLC1A5 inhibition using GPNA reduced calvarial cell proliferation in vitro (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1W</xref>). It is important to note we observed similar results in the developing long bones at both e15.5 and P0 (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1C-V</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2A-I</xref>). Similarly, 2-month-old <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice had reduced osteoblast numbers (exemplified by OCN expression) and significantly less trabecular bone volume as measured by ÂµCT in the distal femur compared to <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> wild-type littermate controls (<xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2J-N</xref>). Collectively, these data indicate <italic>Slc1a5</italic> acts cell-autonomously to regulate osteoprogenitor proliferation and osteoblast differentiation.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Slc1a5 is necessary for osteoblast proliferation and differentiation.</title><p>(<bold>AâD</bold>) von Kossa/Alcian blue staining on <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> (<bold>A,C</bold>) and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> (<bold>B,D</bold>) (N = 4) at E15.5. (<bold>EâJ</bold>) Representative immunofluorescent staining for Proliferating Cell Nuclear Antigen (PCNA) used to quantify proliferation. Endogenous GFP from <italic>Sp7<sup>GFP</sup></italic> shown in (<bold>GâH</bold>) used to quantify PCNA/GFP double positive cells. The numbers in each panel represent the percent GFP, PCNA or double positive cells per GFP positive bone area (dotted line). (<bold>KâV</bold>) Representative alkaline phosphatase (ALPL) staining (<bold>KâL</bold>) or In situ hybridization (<bold>MâV</bold>) for <italic>Col1a1, Spp1, Ibsp</italic> at E15.5 (N = 4) and <italic>Spp1, Bglap</italic> at P0 (N = 3). (<bold>W</bold>) Functional assays of osteoblast differentiation in cOB isolated from <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice. cultured for 14 days in osteogenic media. (<bold>X</bold>) Graphical depiction of EdU incorporation in cOB cells isolated from <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice. Error bars depict SD. * p â¤ 0.05, ** p â¤ 0.005. by an unpaired two-tailed Studentâs <italic>t</italic>-test.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2âsource data 1.</label><caption><title>Contains numerical source data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig2-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>SLC1A5 is necessary for proliferation and endochondral ossification.</title><p>(<bold>AâV</bold>) In situ hybridization for <italic>Ibsp</italic> on p0 skull (<bold>AâB</bold>), representative alkaline phosphatase (ALPL) staining (<bold>CâD</bold>) von Kossa/Alcian blue staining (<bold>EâF</bold>), In situ hybridization (<bold>GâL, OâP, SâV</bold>) for <italic>ColX, MMP13, SP7, Col1a1, Spp1, Ibsp</italic> at E15.5 (N = 4).</p><p>Representative immunofluorescent staining for OSX (<bold>MâN</bold>) or Collagen Type 1 (COL1A1) (<bold>QâR</bold>) at E15.5 in <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice. (<bold>WâY</bold>) Effect of GPNA (0.3 mM) treatment on EdU incorporation (<bold>WâX</bold>) or protein synthesis as determined by <sup>35</sup>S incorporation assay (<bold>Y</bold>). Error bars depict SD. * p â¤ 0.05, ** p â¤ 0.005. by an unpaired two-tailed Studentâs <italic>t</italic>-test.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2âfigure supplement 1âsource data 1.</label><caption><title>Contains numerical source data for <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 2.</label><caption><title>Limb phenotypes at birth and 2 months in <italic>Sp7Cre;Slc1a5fl/fl</italic> mice.</title><p>(<bold>AâB</bold>) Alcian blue/Picrosirius red staining, (<bold>C</bold>) qRT-PCR analyses or in situ hybridization (<bold>DâI</bold>) on <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> femora (N = 5) at P0.</p><p>(<bold>JâK</bold>) Representative Î¼CT (N = 6) used to quantify BV/TV(%) and (<bold>LâN</bold>) OCN immunofluorescent staining and quantification on <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> (N = 4) knockout mice at 2 months of age. Error bars depict SD. * p â¤ 0.05, ** p â¤ 0.005, by an unpaired two-tailed Studentâs <italic>t</italic>-test.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2âfigure supplement 2âsource data 1.</label><caption><title>Contains numerical source data for <xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig2-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig2-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title><italic>Slc1a5</italic> inhibition reduces protein synthesis in osteoblasts</title><p>We next sought to understand how <italic>Slc1a5</italic> regulates proliferation and differentiation. Because <italic>Slc1a5</italic> encodes a neutral amino acid transporter, we hypothesized that <italic>Slc1a5</italic> ablation would primarily affect protein synthesis. To test this hypothesis, we first evaluated protein synthesis directly by monitoring the incorporation of <sup>3</sup>H-proline into protein. <italic>Slc1a5</italic> targeting significantly reduced <sup>3</sup>H-proline incorporation into both collagen and total protein (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1A-B</xref>). Likewise, primary calvarial cells isolated from <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice had significantly reduced protein and collagen synthesis rates in vitro (<xref ref-type="fig" rid="fig3">Figure 3AâB</xref>). These results indicate <italic>Slc1a5</italic> is required for robust protein synthesis in osteoblasts. To test the validity of this conclusion, we evaluated the production of osteoblast proteins in vivo. Consistent with the in vitro data, <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice were characterized by significantly less COL1A1 in both the calvariae and long bones at e15.5 and P0 (<xref ref-type="fig" rid="fig3">Figure 3CâH</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1Q-R</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1E-F</xref>). It is important to note, <italic>Col1a1</italic> mRNA expression was not affected in these mice indicating <italic>Slc1a5</italic> provides amino acids required for robust COL1A1 synthesis. Similarly, <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice had a significant reduction in OSX protein expression as we observed a reduction in the proportion of OSX expressing cells despite no change in <italic>Sp7<sup>GFP</sup></italic> expression (used as a proxy for <italic>Sp7</italic>) in <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> calvariae (<xref ref-type="fig" rid="fig3">Figure 3IâN</xref>). Thus, <italic>Slc1a5</italic> is essential for the synthesis of proteins like OSX to regulate terminal osteoblast differentiation and COL1A1 necessary for bone matrix production.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Slc1a5 is required for robust protein and matrix synthesis in osteoblasts.</title><p>(<bold>AâB</bold>) Radiolabeled <sup>3</sup>H-proline incorporation into total protein (<bold>A</bold>) or collagen (<bold>B</bold>) in cOB cells isolated from <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice. (<bold>CâN</bold>) Representative immunofluorescent staining for Collagen Type 1 (COL1A1) (<bold>CâH</bold>) or OSX (<bold>IâN</bold>) at E15.5 in <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic>(<bold>C,D,E,I,J,K</bold>) and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> (<bold>F,G,H,L,M,N</bold>) mice. Endogenous GFP from <italic>Sp7<sup>GFP</sup></italic> shown in (<bold>C,F,I,L</bold>). Col1a1 intensity was quantified in the GFP-positive region. Endogenous GFP from <italic>Sp7<sup>GFP</sup></italic> shown in (<bold>I, L</bold>) was used to quantify OSX/GFP double positive cells. The numbers in each panel represent the percent GFP, OSX or double positive cells per GFP-positive bone area (dotted line). Inset images show 60 x magnification of the indicated region. * p â¤ 0.05, by an unpaired two-tailed Studentâs <italic>t</italic>-test.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3âsource data 1.</label><caption><title>Contains numerical source data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig3-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>SLC1A5 is necessary for protein synthesis.</title><p>(<bold>AâB</bold>) Radiolabeled <sup>3</sup>H-proline incorporation into total protein (<bold>A</bold>) or collagen (<bold>B</bold>) in cOB cells.</p><p>(<bold>CâH</bold>) Representative immunofluorescent staining for Collagen Type 1 (COL1A1) at P0 in <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic>(<bold>C,E,G</bold>) and <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> (<bold>D,F,H</bold>) mice. Endogenous GFP from <italic>Sp7<sup>GFP</sup></italic> shown in (<bold>CâD</bold>). The value below the merged image is the quantification of Col1a1 intensity in the GFP positive area measured from 4 mice. Inset images are Ã60 magnification of the indicated region. * p â¤ 0.05, by an unpaired two-tailed Studentâs <italic>t</italic>-test.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3âfigure supplement 1âsource data 1.</label><caption><title>Contains numerical source data for <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig3-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title><italic>Slc1a5</italic> provides glutamine and asparagine to regulate amino acid homeostasis</title><p>We next sought to define the molecular substrates of SLC1A5 in osteoblasts. First, we determined the effect of <italic>Slc1a5</italic> knockout on downstream metabolites using mass spectrometry. <italic>Slc1a5</italic> targeting significantly diminished the intracellular abundance of many amino acids including reported substrates of SLC1A5 (e.g. asparagine, glutamine, and alanine) as well as amino acids not known to be transported by SLC1A5 (e.g. glutamate, lysine, histidine, aspartate, glycine, and proline) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Moreover, <italic>Slc1a5</italic> deletion also reduced the abundance of select TCA cycle intermediates including fumarate, malate, citrate, and a-ketoglutarate (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1A</xref>). Interestingly, the uptake of many of these amino acids was unaffected in <italic>Slc1a5</italic>-deficient cells as only glutamine and to a lesser extent asparagine uptake was diminished in <italic>Slc1a5</italic> targeted calvarial cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Conversely, we observed a compensatory increase in the uptake of lysine in <italic>Slc1a5</italic>-deficient calvarial cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Similar results were obtained upon acute SLC1A5 inhibition indicating SLC1A5 transports glutamine and asparagine in osteoblasts (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1B</xref>). <italic>Slc1a5</italic>-deficient cells had many cellular changes consistent with decreased amino acid concentrations. For example, <italic>Slc1a5</italic> inhibition significantly increased EIF2a Ser51 phosphorylation, a marker of amino acid depletion (<xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1C</xref>). Additionally, we observed a significant reduction in mTORC1 activity, as both ribosomal protein S6 Ser240/244 phosphorylation and Eif4ebp1 Ser65 phosphorylation were significantly reduced in <italic>Slc1a5</italic>-deficient calvarial cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Interestingly, mTOR activation was not affected by acute SLC1A5 inhibition indicating decreased mTORC1 signaling may be a secondary effect of <italic>Slc1a5</italic> deletion. Collectively, these data indicate SLC1A5 provides glutamine and asparagine to regulate intracellular amino acid homeostasis in osteoblast progenitors.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Slc1a5 provides glutamine and asparagine to maintain amino acid homeostasis.</title><p>(<bold>A</bold>) Effect of <italic>Slc1a5</italic> targeting on intracellular amino acid concentration measured by mass spectrometry.(<bold>B</bold>) Effect of <italic>Slc1a5</italic> targeting on the uptake of indicated radiolabeled amino acids. (<bold>C</bold>) Western Blot analyses of the effect of <italic>Slc1a5</italic> targeting on mTORC1 signaling and Eif2a phosphorylation. Phospho-proteins normalized to respective total protein. ASCT2 normalized to Î±-tubulin. sgRNAs targeting luciferase were used as a negative control. Fold changeÂ± SD for <italic>sgSlc1a5</italic> over <italic>sgLuc</italic> in three independent experiments. * p â¤ 0.05 by an unpaired two-tailed Studentâs <italic>t</italic>-test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4âsource data 1.</label><caption><title>Contains numerical and uncropped western blot source data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title>NEAA can partially rescue differentiation but not proliferation.</title><p>(<bold>A</bold>) Effect of <italic>Slc1a5</italic> targeting on intracellular concentration of Pyruvate, Lactate, Succinate, Malate, citrate, and Î± ketoglutarate (Î±KG).</p><p>(<bold>B</bold>) Effect of GPNA treatment on the uptake of indicated radiolabeled amino acids. (<bold>C</bold>) Western blot analyses of the effect of GPNA treatment on Eif2a phosphorylation and mTORC1 signaling. Phospho-proteins normalized to respective total protein. HCL treated cells were used as negative control. Fold changeÂ± SD for HCL over GPNA treated in three independent experiments. (<bold>DâE</bold>) Effect of NEAA supplementation on osteoblast marker gene induction as measured by qRT-PCR (<bold>D</bold>) or EDU incorporation (<bold>E</bold>) in sg<italic>Slc1a5</italic> cells. * p â¤ 0.05, ** p â¤ 0.005, ** p â¤ 0.0005, by multiple unpaired <italic>t</italic>-tests (<bold>AâB</bold>) or ordinary one-way ANOVA with Tukeyâs multiple comparisons (<bold>DâE</bold>). Error bars depict SD.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4âfigure supplement 1âsource data 1.</label><caption><title>Contains numerical and uncropped western blot source data for <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig4-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Glutamine depletion mimics the effects of <italic>Slc1a5</italic> deletion</title><p>We next sought to understand the importance of both glutamine and asparagine for cellular function. To do this, we cultured naive calvarial cells in the absence of glutamine or in media treated with asparaginase to deplete asparagine. Depletion of either glutamine or asparagine from the media similarly inhibited the induction of terminal osteoblast genes <italic>Ibsp</italic> and <italic>Bglap</italic> and prevented matrix mineralization (<xref ref-type="fig" rid="fig1">Figures 1BâC ,</xref>â<xref ref-type="fig" rid="fig5">5AâB</xref>). While this was reminiscent of <italic>Slc1a5</italic> ablation, it is important to note that glutamine withdrawal had a more profound effect on osteoblast differentiation compared to either asparagine depletion or <italic>Slc1a5</italic> ablation. We next evaluated mTORC1 activity and EIF2a phosphorylation. Depletion of glutamine, but not asparagine, mimicked the effects of <italic>Slc1a5</italic> targeting on both EIF2a Ser51 phosphorylation and mTORc1 activity (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Consistent with this, cells cultured in the absence of glutamine had reduced COL1A1 expression and decreased proliferation like <italic>Slc1a5</italic> deficient cells (<xref ref-type="fig" rid="fig5">Figure 5CâD</xref>). On the other hand, culturing cells in the absence of asparagine had no discernable effect on either pSer51 Eif2a, pSer240/244 S6rp, or COL1A1 expression and enhanced proliferation as determined by increased EdU incorporation (<xref ref-type="fig" rid="fig5">Figure 5CâD</xref>). Importantly, culturing cells in the absence of either glutamine or asparagine had no effect on cell viability (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). From these data, we conclude SLC1A5 primarily provides glutamine to regulate amino acid homeostasis necessary for proliferation and osteoblast differentiation. Additionally, SLC1A5 provides asparagine which is essential for terminal osteoblast differentiation and matrix mineralization.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Glutamine and asparagine are required for osteoblast differentiation.</title><p>(<bold>AâB</bold>) Functional assays (<bold>A</bold>) or qRT-PCR analyses (<bold>B</bold>) of the effect of glutamine withdrawal or asparaginase treatment on cOB cultured in osteogenic media for 14 days. (<bold>C</bold>) Western blot analyses of the effect of glutamine or asparagine withdrawal on mTORC1 signaling, Eif2a phosphorylation or COL1A1 expression. Phospho-proteins normalized to respective total protein. COL1A1 normalized to beta-actin. Fold changeÂ± SD for three independent experiments. * p â¤ 0.05 by an unpaired 2-tailed Studentâs <italic>t</italic>-test. (<bold>DâE</bold>) Effect of glutamine or asparagine withdrawal on EdU incorporation (<bold>D</bold>) or cell viability (<bold>E</bold>) as determined by Annexin V staining.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5âsource data 1.</label><caption><title>Contains numerical and uncropped western blot source data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig5-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig5-v2.tif"/></fig></sec><sec id="s2-6"><title>Glutamine and asparagine-dependent amino acid synthesis is essential for protein synthesis</title><p>We next investigated how osteoblast utilize glutamine and asparagine. Since SLC1A5 ablation reduced intracellular amino acids, we hypothesized osteoblasts rely on glutamine and asparagine metabolism to maintain cellular amino acid pools. To test the validity of this hypothesis, we traced the relative contribution of glutamine or asparagine into amino acids directly. Consistent with previous reports, glutamine carbon contributes to all TCA cycle intermediates and was significantly enriched in several amino acids (e.g. glutamate, aspartate, alanine, and proline) found to be reduced in <italic>Slc1a5</italic> targeted cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1A</xref>). Similarly, glutamine nitrogen was significantly enriched in glutamate, aspartate, alanine, serine, glycine and proline (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Consistent with the minor effects of asparagine withdrawal on markers of amino acid depletion, asparagine carbon was enriched only in aspartate, malate, fumarate, and citrate (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1A</xref>). On the other hand, asparagine nitrogen was enriched in aspartate, glutamate, proline, serine, and alanine (<xref ref-type="fig" rid="fig6">Figure 6AâB</xref>). Thus, glutamine contributes both carbon and nitrogen for amino acid biosynthesis whereas asparagine carbon is used only for aspartate biosynthesis while asparagine nitrogen is used in transamination reactions. Importantly, the amino acids derived from either glutamine carbon (e.g. Glu, Ala, Asp, Pro) and nitrogen (e.g. Glu, Ala, Asp, Ser, Gly and Pro) and asparagine carbon (e.g. Asp) and nitrogen (e.g. Asp, Pro, Ala, Ser) were significantly enriched in total protein (<xref ref-type="fig" rid="fig6">Figure 6CâD</xref>). Rescue experiments found NEAA did not rescue proliferation but could rescue the induction of terminal osteoblast marker genes like <italic>Ibsp</italic> and to a lesser extent <italic>Bglap</italic> in <italic>Slc1a5</italic>-deficient cells (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>). These data indicate <italic>Slc1a5</italic> provides glutamine and asparagine that are used for de novo synthesis of many amino acids (e.g. Glu, Asp, Ala, Ser, Gly, and Pro) that can be incorporated into nascent protein in osteoblasts.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Glutamine and asparagine are utilized for de novo amino acid biosynthesis.</title><p>(<bold>AâB</bold>) Fractional contribution of [U-<sup>13</sup>C]glutamine or [U-<sup>13</sup>C]asparagine (<bold>A</bold>) or [Î±â<sup>15</sup>N]glutamine or [Î±â15N]asparagine (<bold>B</bold>) to asparagine, aspartate, glutamate, proline, serine, and alanine. (<bold>CâD</bold>) Fractional contribution of [U-<sup>13</sup>C]glutamine or [U-<sup>13</sup>C]asparagine (<bold>C</bold>) or [Î±â15N]glutamine or [Î±â15N]asparagine (<bold>D</bold>) to asparagine, aspartate, glutamate, proline, serine, and alanine in total protein. (<bold>EâF</bold>) Effect of BPTES treatment on the fractional contribution of [U-<sup>13</sup>C]glutamine (<bold>E</bold>) or [Î±â15N]glutamine (<bold>F</bold>) to amino acids. * p â¤ 0.05, ** p â¤ 0.005, *** p â¤ 0.0005, **** p â¤ 0.00005 by ordinary one-way ANOVA with Tukeyâs multiple comparisons. (<bold>G</bold>) Effect of GLS inhibition on intracellular amino acid concentration measured by mass spectrometry. * p â¤ 0.05, multiple unpaired <italic>t</italic>-tests. Error bars depict SD.(<bold>H</bold>) Western blot analyses of the effects of BPTES treatment on mTORC1 signaling, Eif2a phosphorylation and COL1A1 expression. Phospho-proteins normalized to respective total protein. COL1A1 normalized to beta-actin. Fold changeÂ± SD for three independent experiments. * p â¤ 0.05 by an unpaired two-tailed Studentâs <italic>t</italic>-test. (<bold>I</bold>) Effect of GLS inhibition on protein synthesis as determined by the rate of <sup>3</sup>H Proline incorporation into total protein. * p â¤ 0.05 by an unpaired two-tailed Studentâs <italic>t</italic>-test. Error bars depict SD.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6âsource data 1.</label><caption><title>Contains numerical and uncropped western blot source data for <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig6-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 1</label><caption><title>Inhibiting glutamine metabolism recapitulates molecular effects of SLC1A5 ablation.</title><p>(<bold>A</bold>) Fractional contribution of [U-<sup>13</sup>C]glutamine or [U-<sup>13</sup>C]asparagine to fumarate, malate, succinate, and Citrate.</p><p>(<bold>B</bold>) Effect of BPTES treatment on the fractional contribution of [U-<sup>13</sup>C]glutamine to fumarate, malate, succinate, and Citrate. (<bold>C</bold>) Effect of BPTES on EdU incorporation. (<bold>D</bold>) Effect of GLS inhibition on tRNA charging. Error bars depict SD. (<bold>E</bold>) <italic>Gls</italic> Crispr targeting strategy. (<bold>F</bold>) PCR analysis of targeted region. Arrow denotes untargeted <italic>Gls</italic> band. (<bold>G</bold>) Western blot analyses of the effect of <italic>Gls</italic> targeting. sgRNAs targeting luciferase and mCherry (denoted sgLuc) were used as a negative control. * p â¤ 0.05, by an multiple unpaired <italic>t</italic>-tests. Error bars depict SD.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6âfigure supplement 1âsource data 1.</label><caption><title>Contains numerical and uncropped western blot source data for <xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71595-fig6-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71595-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Next, we sought to determine if glutamine-dependent amino acid synthesis was required for the high rate of protein synthesis in osteoblasts. We focused on glutamine because glutamine was more widely used for amino acid synthesis, and glutamine withdrawal more completely phenocopied the cellular effects of <italic>Slc1a5</italic> targeting. To do this, we inhibited the enzyme glutaminase (GLS) which catalyzes the first rate-limiting step in glutamine metabolism. GLS inhibition using BPTES resulted in cellular effects similar to <italic>Slc1a5</italic> ablation. GLS inhibition significantly reduced glutamine carbon and nitrogen contribution to amino acid synthesis and reduced the intracellular concentrations of glutamate, aspartate, alanine, serine, and glycine concentrations (<xref ref-type="fig" rid="fig6">Figure 6EâG</xref>). Consistent with reduced amino acid concentrations, GLS inhibition increased the presence of uncharged Glu, Asp, and Pro tRNA without affecting either Gln or Val tRNA charging (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1D</xref>). Finally, GLS inhibition induced eIF2Î± Ser51 phosphorylation and reduced S6 Ser240/244 phosphorylation (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). Consistent with these molecular changes, GLS inhibition significantly reduced EdU incorporation and COL1A1 expression (<xref ref-type="fig" rid="fig6">Figure 6HâI</xref>). Importantly, <italic>Gls</italic> targeting reduced overall protein synthesis like <italic>Slc1a5</italic> targeting (<xref ref-type="fig" rid="fig6">Figure 6I</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1E-G</xref>). These data highlight the importance of de novo amino acid synthesis to maintain amino acid homeostasis and promote proliferation and protein synthesis in osteoblasts.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we present data demonstrating that SLC1A5 is a critical regulator of osteoblast proliferation, differentiation and bone formation. Osteoblasts increase <italic>Slc1a5</italic> expression as they undergo differentiation and increase bone matrix production. Genetically inhibiting SLC1A5 activity in preosteoblasts results in delayed endochondral and intramembranous ossification. Delayed bone development is the result of decreased osteoprogenitor proliferation as well as a reduction in overall osteoblast differentiation. <italic>Slc1a5</italic> deficient osteoblasts have reduced protein synthetic activity which manifests in reduced OSX and COL1A1 protein expression. COL1A1 is the major organic component of bone matrix and OSX is required for terminal osteoblast differentiation (<xref ref-type="bibr" rid="bib33">Nakashima et al., 2002</xref>). Mechanistically, SLC1A5 primarily provides glutamine and to a lesser extent asparagine in osteoblasts.</p><p>Glutamine is an essential nutrient in osteoblasts. We and others have shown that glutamine metabolism contribute to many downstream metabolites in osteoblasts including Î±KG, non-essential amino acids (NEAA) and the tripeptide antioxidant glutathione (<xref ref-type="bibr" rid="bib23">Karner et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Yu et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Stegen et al., 2021</xref>). These different studies have demonstrated these glutamine derived metabolites regulate distinct processes during osteoblast differentiation. For example, Î±KG is essential for skeletal stem cell proliferation, GSH regulates osteoblast viability while NEAA are important for differentiation (<xref ref-type="bibr" rid="bib66">Yu et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Stegen et al., 2021</xref>). We have extended these previous findings by identifying SLC1A5 as the primary glutamine transporter in osteoblasts. SLC1A5 is responsible for the majority of glutamine uptake importing 53.5 % of glutamine in osteoblasts. In addition, <italic>Slc1a5</italic> is a minor contributor to asparagine uptake importing only 19.5 % of asparagine in osteoblasts (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Consistent with our own and others previous reports, we found glutamine is a critical nutrient at all stages of osteoblast differentiation whereas asparagine is more important for terminal osteoblast differentiation. To our knowledge, this represents the first demonstration of the necessity of asparagine for osteoblast differentiation. Although, osteoblasts likely rely heavily on other transporters in addition to SLC1A5 to provide asparagine during differentiation.</p><p>Osteoblasts increase SLC1A5 expression to supply glutamine and asparagine which are used to maintain amino acid homeostasis. Interestingly, glutamine was more widely used for NEAA biosynthesis as our tracing experiments found glutamate, alanine, serine, aspartate, proline, and glycine were all synthesized from either glutamine carbon or nitrogen. Conversely, only aspartate was synthesized using asparagine carbon whereas Asp, Glu, Ala, and Ser were synthesized using asparagine nitrogen albeit at lower levels compared to glutamine (<xref ref-type="fig" rid="fig6">Figure 6AâB</xref>). It is important to note that while we focused our analyses on amino acid biosynthesis, our data does not preclude a role for glutamine and asparagine to support osteoblast proliferation or differentiation by providing other metabolites. Consistent with this, NEAA could not rescue proliferation in <italic>Slc1a5</italic> deficient cells (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1E</xref>). Moreover, the functional significance of asparagine derived amino acids in osteoblasts remains enigmatic. The effects of asparagine depletion on osteoblast differentiation may be due to direct effects on protein synthesis, reduction of select asparagine sensitive proteins or loss of an as yet undefined asparagine derived metabolite (e.g. nucleotides). Future studies into the role and downstream metabolism of asparagine in osteoblasts are warranted.</p><p>It is interesting that glutamine and asparagine metabolism impinge upon aspartate biosynthesis in osteoblasts. Aspartate synthesis is critical for proliferation by providing both carbon and nitrogen for synthetic reactions (<xref ref-type="bibr" rid="bib3">Birsoy et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Sullivan et al., 2015</xref>). Thus, glutamine (and asparagine when glutamine is limiting) likely regulate proliferation in part by providing both carbon and nitrogen for aspartate biosynthesis (<xref ref-type="bibr" rid="bib41">Pavlova et al., 2018</xref>). Aspartate synthesis likely occurs as part of the malate aspartate shuttle which is critical to regenerate oxidized NAD<sup>+</sup> to maintain high rates of glycolysis in osteoblasts (<xref ref-type="bibr" rid="bib30">Lee et al., 2020</xref>). While we do not completely understand the metabolism of aspartate in osteoblasts, the aspartate derived from both glutamine and asparagine was enriched in total protein (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Interestingly, while glutamine contributed more to aspartate biosynthesis than asparagine, asparagine-derived aspartate was more highly enriched in total protein. This suggests disparate pools of aspartate exist in osteoblasts and that the metabolic fates for these glutamine- or asparagine-derived aspartate pools vary. For example, glutamine derived aspartate may contribute more to nucleotide biosynthesis to facilitate osteoblast proliferation whereas asparagine derived aspartate is used more for protein and matrix synthesis.</p><p>Proliferation is one of the initial stages of the osteoblast differentiation process. Proliferation is associated with increased demand for glucose and amino acids to support both nucleotide and NEAA biosynthesis required for cell division (<xref ref-type="bibr" rid="bib16">Guntur et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Karner and Long, 2018</xref>; <xref ref-type="bibr" rid="bib13">Flanagan and Nichols, 1964</xref>; <xref ref-type="bibr" rid="bib19">Hosios et al., 2016</xref>). To fulfil this need, proliferating cancer cells increase amino acid transporter expression to enhance amino acid supply (<xref ref-type="bibr" rid="bib2">Bhutia et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Hassanein et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">DeBerardinis et al., 2008</xref>; <xref ref-type="bibr" rid="bib21">Jones et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Kiyokawa et al., 1996</xref>; <xref ref-type="bibr" rid="bib27">Krall et al., 2016</xref>). Here, we find that <italic>Slc1a5</italic> provides glutamine and asparagine to osteoblasts, but that only glutamine is required for proliferation. This is consistent with recent reports that asparagine is important for proliferation only when glutamine is limited (<xref ref-type="bibr" rid="bib41">Pavlova et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Vander Heiden and DeBerardinis, 2017</xref>; <xref ref-type="bibr" rid="bib68">Zhang et al., 2014</xref>). Glutamine is an essential nutrient in proliferating cells (<xref ref-type="bibr" rid="bib9">Eagle, 1955</xref>), and recent studies found glutamine and its metabolism are critical for proliferation in osteoblast progenitor cells (<xref ref-type="bibr" rid="bib66">Yu et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Stegen et al., 2021</xref>). The precise mechanism by which SLC1A5 regulates proliferation remains unclear as amino acid supplementation was unable to rescue proliferation. This may be because NEAA uptake is inherently limited in osteoblasts resulting in the need for amino acid biosynthesis. Alternatively, glutamine catabolism provides amino acids and other intermediate metabolites (e.g. Î±-KG) to support proliferation. Consistent with this, we and others have shown that either Î±-KG or NEAA can rescue proliferation in GLS-deficient skeletal stem cells or osteoblasts respectively (<xref ref-type="bibr" rid="bib66">Yu et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Stegen et al., 2021</xref>).</p><p>During differentiation, osteoblasts increase their capacity for protein synthesis and secretion. Here, we find that <italic>Slc1a5</italic> expression is required for robust protein synthesis in osteoblasts. This effect is likely regulated by multiple factors. First, <italic>Slc1a5</italic> provides glutamine and asparagine that are likely directly incorporated into nascent protein. Second, our tracing data shows both glutamine and asparagine are used for de novo amino acid synthesis to support protein synthesis. Third, <italic>Slc1a5</italic> provides glutamine to activate the mechanistic target of rapamycin complex 1 (mTORC1), an important regulator of both osteoblast proliferation and differentiation (<xref ref-type="bibr" rid="bib35">Nicklin et al., 2009</xref>; <xref ref-type="bibr" rid="bib51">Singha et al., 2008</xref>; <xref ref-type="bibr" rid="bib63">Xian et al., 2012</xref>; <xref ref-type="bibr" rid="bib6">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Fitter et al., 2017</xref>). mTORC1 is tightly regulated by amino acid availability and functions to increase protein synthesis when amino acids are available. Consistent with this, <italic>Slc1a5</italic>-deficient osteoblasts had decreased mTORC1 activation and reduced protein synthesis (<xref ref-type="fig" rid="fig3">Figures 3AâB ,</xref>â<xref ref-type="fig" rid="fig4">4C</xref>). Finally, <italic>Slc1a5</italic>-deficient osteoblasts were characterized by robust activation of the integrated stress response (ISR). When amino acids are limiting, uncharged tRNA activates the kinase general control nonderepressible 2 (GCN2) which phosphorylates eukaryotic initiation factor 2 a (eIF2a) to attenuate global protein synthesis (<xref ref-type="bibr" rid="bib67">Zhang et al., 2002</xref>; <xref ref-type="bibr" rid="bib64">Ye et al., 2010</xref>; <xref ref-type="bibr" rid="bib28">Kroemer et al., 2010</xref>; <xref ref-type="bibr" rid="bib38">Pakos-Zebrucka et al., 2016</xref>). These molecular changes in <italic>Slc1a5</italic>-deficient osteoblasts are primarily the result of reduced glutamine uptake as our drop out experiments found glutamine but not asparagine withdrawal reduced mTORC1 activation and increased ISR like <italic>Slc1a5</italic> ablation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Moreover, inhibiting glutamine catabolism similarly affected mTORC1 and ISR activation (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). Thus, <italic>Slc1a5</italic> provides glutamine used to maintain amino acid homeostasis to regulate protein synthesis directly and indirectly downstream of mTORC1 and GCN2-dependent ISR.</p><p>In summary, we have defined the necessity and the molecular substrates of <italic>Slc1a5</italic> in osteoblasts. Our data indicates that SLC1A5 is the primary glutamine transporter in osteoblasts. In addition to glutamine, SLC1A5 acts cell autonomously in osteoblasts to provide asparagine, both of which are essential for osteoblast differentiation. These data highlight an elegant mechanism by which osteoblasts both directly obtain and synthesize the requisite amino acids to support osteoblast differentiation and bone formation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic Reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57Bl/6 J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic Reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Rosa26Cas9</italic></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:024858">IMSR_JAX:024858</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic Reagent <italic>(M. musculus)</italic></td><td align="left" valign="bottom"><italic>Rosa26Flpe</italic></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:003946">IMSR_JAX:003946</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic Reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Sp7tTA;tetOeGFP/Cre</italic></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/16854976/">16854976</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:006361">IMSR_JAX:006361</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic Reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Slc1a5</italic><sup><italic>flox</italic></sup></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See <bold>Methods â Mouse strains</bold> for more information.</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ascorbic acid</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#A4544</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Î²-glycerophosphate</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#G9422</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">one-step NBT/BCIP solution</td><td align="left" valign="bottom">Thermofisher</td><td align="left" valign="bottom">Cat#PI34042</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-(2,3,4-<sup>3</sup>H)Glutamine</td><td align="left" valign="bottom">Perkin Elmer</td><td align="left" valign="bottom">Cat#NET551250UC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-(<sup>14</sup>C)Alanine</td><td align="left" valign="bottom">Perkin Elmer</td><td align="left" valign="bottom">Cat#EC266E250UC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-(2,3,-<sup>3</sup>H)Proline</td><td align="left" valign="bottom">Perkin Elmer</td><td align="left" valign="bottom">Cat#NET483250UC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-(2,3,-<sup>3</sup>H)Aspartic acid</td><td align="left" valign="bottom">Perkin Elmer</td><td align="left" valign="bottom">Cat#NET390V001MC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-(4,5-<sup>3</sup>H(N))Lysine</td><td align="left" valign="bottom">Perkin Elmer</td><td align="left" valign="bottom">Cat#NEC280E050UC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-(2,3,<sup>3</sup> H)Asparagine</td><td align="left" valign="bottom">American Radiolabeled Chemicals</td><td align="left" valign="bottom">Cat#ART-0500â250</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">[U-<sup>13</sup>C]glutamine,</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#605,166</td><td align="left" valign="bottom">Used at 2 mM final concentration</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">[Î±-<sup>15</sup> N]glutamine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#486,809</td><td align="left" valign="bottom">Used at 2 mM final concentration</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">[U-<sup>13</sup>C]Asparagine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#579,866</td><td align="left" valign="bottom">Used at 0.33 mM final concentration</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">[Î±-<sup>15</sup> N] Asparagine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#485,896</td><td align="left" valign="bottom">Used at 0.33 mM final concentration</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">AP substrate BM purple</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat#11442074001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ECL substrate</td><td align="left" valign="bottom">Biorad</td><td align="left" valign="bottom">Cat#1705060</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">super signal West Femto ECL.</td><td align="left" valign="bottom">Thermofisher</td><td align="left" valign="bottom">Cat#1705060</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Eif2Î± (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10692650">AB_10692650</ext-link></td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">pSer51 Eif2Î± (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2096481">AB_2096481</ext-link></td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">pSer240/244 S6rp(rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331682">AB_331682</ext-link></td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">S6rp (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331355">AB_331355</ext-link></td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Î±-tubulin (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2619646">AB_2619646</ext-link></td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Î±-actin (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330288">AB_330288</ext-link></td><td align="left" valign="bottom">(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP goat anti-rabbit (goat polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2099233">AB_2099233</ext-link></td><td align="left" valign="bottom">(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP anti-mouse (horse polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330924">AB_330924</ext-link></td><td align="left" valign="bottom">(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">COL1A1 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2797597">AB_2797597</ext-link></td><td align="left" valign="bottom">(1:2000) WB (1:1000) IF</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">OSX (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2194492">AB_2194492</ext-link></td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PCNA (mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2160343">AB_2160343</ext-link></td><td align="left" valign="bottom">(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">goat anti mouse 568 (goat unknown clonality)</td><td align="left" valign="bottom">Thermofisher</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_141359">AB_141359</ext-link></td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">goat anti Rabbit 568 (goat polyclonal)</td><td align="left" valign="bottom">Thermofisher</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_143157">AB_143157</ext-link></td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Iscript Reverse transcription kit</td><td align="left" valign="bottom">Biorad</td><td align="left" valign="bottom">Cat#1708841</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SYBR green</td><td align="left" valign="bottom">Biorad</td><td align="left" valign="bottom">Cat#1725275</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Click-iT EdU Cell Proliferation Imaging Kit</td><td align="left" valign="bottom">Invitrogen,</td><td align="left" valign="bottom">Cat#C10337</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#C10420</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Apoptosis Assay Kit (Cat# 22837).</td><td align="left" valign="bottom">AAT BIO</td><td align="left" valign="bottom">Cat# 22,837</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">AP substrate BM purple</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat#11442074001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software Algorithm</td><td align="left" valign="bottom">Graphpad 6</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mouse strains</title><p>C57Bl/6 J (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link>), <italic>Rosa26Cas9</italic> (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:1MSR_JAX:024858">1MSR_JAX:024858</ext-link>), <italic>Sp7tTA;tetOeGFP/Cre</italic> (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:006361">IMSR_JAX:006361</ext-link>) (denoted in the text as <italic>Sp7Cre</italic>), and <italic>Rosa26Flpe</italic> (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:003946">IMSR_JAX:003946</ext-link>) mouse strains were obtained from the Jackson Laboratory. The <italic>Slc1a5<sup>flox</sup></italic> mouse strain was generated by the Duke Cancer Institute Transgenic Core facility. Briefly, LoxP sites flanking exon two and a frt PGK neo-cassette were inserted in to the endogenous <italic>Slc1a5</italic> locus using homologous recombination (Fig. S1). The chimeric mice containing the targeting vector were then crossed to the <italic>Rosa26Flpe</italic> mouse to remove the neomycin cassette. All mice were housed at 23 Â°C on a 12 hr light/dark cycle and maintained on PicoLab Rodent Diet 290 (Lab diet#5053, St. Louis, MO). Timed pregnant females euthanized, and embryos were analyzed at E14.5, E15.5, E16.5, and P0. <italic>Sp7tTA;tetOeGFP/Cre</italic> mice expresses GFP and Cre recombinase under the control of the <italic>Sp7</italic> promoter. We evaluated GFP as a proxy for <italic>Sp7</italic> mRNA expression. The <italic>Sp7tTA;tetOeGFP/Cre</italic> mice have a partially penetrant bone phenotype. To control for this, in all genetic experiments, <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> âknockoutâ mice are always compared to <italic>Sp7Cre;Slc1a5<sup>fl/+</sup></italic> as âwild typeâ littermate controls. All animal studies were approved by the animal studies committees at Duke University and the University of Texas Southwestern Medical Center at Dallas.</p></sec><sec id="s4-2"><title>Cell culture</title><p>P3 pups were euthanized and the parietal and frontal bones were isolated according to standard protocols. The membranous tissue was removed, and the bones were washed and cleaned with PBS. The calvaria was chopped and four sequential 10 min digestions were performed with 1 mg/ml Collagenase P in a shaking incubator at 37 Â°C. The first digestion was discarded, and the rest were combined. The digested calvarial cells were centrifuged and plated with Î±-MEM (GIBCO) supplemented with 15 % FBS (Invitrogen). The cells were seeded at 50,000 cells/ml. To initiate osteoblast differentiation the growth media was replaced with Î±-MEM with 10 % FBS, 50 mg/ml ascorbic acid (Sigma) and 10 mM Î²-glycerophosphate (Sigma). RNA was isolated at day 7 after mineralization media was added. At day 14, alizarin red and Von kossa staining was performed to visualize matrix mineralization. Alkaline phosphatase staining was performed using the one-step nitro-blue tetrazolium (NBT) and 5-bromo-4-chloro-3â-indolyphosphate p-toluidine salt (BCIP) solution (Thermofisher). For amino acid rescue experiments, cells were cultured for either 24 hr (proliferation) or 7 days in Î±-MEM supplemented to the indicated concentration with the following amino acids: 0.67 mM glycine, 0.28 mM alanine, 0.23 mM aspartic acid, 0.2 mM histidine, 0.24 mM serine, 0.35 mM proline, 0.4 mM lysine, and 0.5 mM arginine.</p><p>CRISPR/Cas9 targeting sgRNA vectors were purchased from the Genome Engineering and iPSC Center at Washington University School of Medicine. cOB were isolated from <italic>Rosa<sup>Cas9</sup></italic> mice and were infected with five lentiviral delivered short guide RNAs targeting exons 4â6 of either <italic>Slc1a5</italic> (sgSlc1a5) or <italic>Gls</italic> (sgGls) (Fig. S1 and S6). As a control cOB were infected with sgRNAs targeting the open-reading frames of Luciferase and mCherry as a control (designated sgLuc in text and Fig.s). sgRNA sequences are listed in <xref ref-type="table" rid="table1">Table 1</xref>. To make virus, 293T cells were cotransfected with the lentiviral vector expressing short guide RNAs, pMD2.g and psPax2. After 48 hr of transfection, the media containing the virus was collected and filtered through 0.45Âµ m filter. cOB were cultured to 50 % confluency and were infected for 24 hr followed by recovery in regular media for another 24 hr.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>sgRNA sequences.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Slc1a5.g4</th><th align="left" valign="bottom">ATTGATCTCCCGCTGGATACNGG</th></tr></thead><tbody><tr><td align="left" valign="bottom">Slc1a5.g1</td><td align="left" valign="bottom">ACCCGTTGGAATCCTGTTCCNGG</td></tr><tr><td align="left" valign="bottom">Slc1a5.g10</td><td align="left" valign="bottom">AAAATCCCTATCGATTCCTGNGG</td></tr><tr><td align="left" valign="bottom">Slc1a5.g17</td><td align="left" valign="bottom">AGAAGAGGTCCCGAAAGCAGNGG</td></tr><tr><td align="left" valign="bottom">Slc1a5.g31</td><td align="left" valign="bottom">CCAGGAGCCCGTGGATGGCGNGG</td></tr><tr><td align="left" valign="bottom">MS344.Gls.g5</td><td align="left" valign="bottom">ATATAACTCATCGATGTGTGNGG</td></tr><tr><td align="left" valign="bottom">MS344.Gls.g3</td><td align="left" valign="bottom">GTGCTAAAAAGCAGTCTGGANGG</td></tr><tr><td align="left" valign="bottom">MS345.Gls.g3</td><td align="left" valign="bottom">CAAATTCAGTCCTGATTTGTNGG</td></tr><tr><td align="left" valign="bottom">MS346.Gls.g14</td><td align="left" valign="bottom">ATATTTCAGGGGTTTTACACNGG</td></tr><tr><td align="left" valign="bottom">MS346.Gls.g1</td><td align="left" valign="bottom">TGCAATTGCTGTTAATGACCNGG</td></tr><tr><td align="left" valign="bottom">SP498.mCherry.g17</td><td align="left" valign="bottom">CAAGTAGTCGGGGATGTCGGNGG</td></tr><tr><td align="left" valign="bottom">SP498.mCherry.g19</td><td align="left" valign="bottom">AGTAGTCGGGGATGTCGGCGNGG</td></tr><tr><td align="left" valign="bottom">SP499.Luc.g3</td><td align="left" valign="bottom">CAATTCTTTATGCCGGTGTTNGG</td></tr><tr><td align="left" valign="bottom">SP399.Luc.g4</td><td align="left" valign="bottom">GTGTTGGGCGCGTTATTTATNGG</td></tr></tbody></table></table-wrap></sec><sec id="s4-3"><title>Uptake assays and proline incorporation assay</title><p>Confluent primary cells were washed ones with PBS and two additionally washes with Krebs Ringer Hepes (KRH) (120 mM NaCl, 5 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 25 mM NaHCO<sub>3</sub>, 5 mM HEPES, 1 mM D-Glucose, pH 8). Cells were then treated for 5 min with KRH containing 4 Î¼Ci/mL of either L-(2,3,4-<sup>3</sup>H)Glutamine, L-(<sup>14</sup>C)Alanine, L-(2,3,-<sup>3</sup>H)Proline, L-(2,3,-<sup>3</sup>H)Aspartic acid, L-(4,5-<sup>3</sup>H(N))Lysine, or L-(2,3,-<sup>3</sup>H)Asparagine. After 5 min, the uptake was terminated by washing the cells three times with ice cold KRH. Cells were then scraped in 1 mL of dH<sub>2</sub>O and lysed by sonication for 1 min with 1 second pulses at 20 % amplitude. The lysate was then centrifuged and mixed with 8 mL scintillation liquid. The counts per minute (CPM) were measured using a Beckman LS6500 scintillation counter. Proline incorporation assay was performed on confluent cells in a 12-well plate. The cells were washed ones with PBS and two additional washes with KRH. The cells were incubated with 4 Î¼Ci/mL L (2,3,-<sup>3</sup>H) Proline in KRH at 37 C for 3 hr. The uptake was terminated with three washes of cold KRH, and the cells were scraped with 150 Î¼l RIPA. The lysates were then cleared and 90 Î¼l of the protein was precipitated with 10 % tricholoroacetic acid (TCA). The pellet was washed three times with 5%TCA and resuspended with 1 ml 0.2 N NaOH. A total of 100 Î¼l of the lysate was saved to measure proline incorporation in total protein. The remaining lysate was separated in to two 400 Î¼l parts, to one-part 200 Î¼l of 60 Î¼m HEPES containing 10 units of collagenase was added and to the second part only HEPES was added. The lysates were incubated at 37 C for 2 hr, followed by precipitation of undigested protein with 10%TCA. The supernatant was added to 8 ml of scintillation liquid to measure proline incorporation in collagen using a Beckman LS6500 scintillation counter.</p></sec><sec id="s4-4"><title>RT-PCR</title><p>RNA was isolated using the Qiagen RNAeasy kit. 500 ng of RNA was reverse transcribed to cDNA using Iscript Reverse transcription kit (Biorad). The cDNA was diluted 1:10. qPCR reaction was setup using SYBR green (Biorad), 2Î¼l of diluted cDNA and 0.1 Î¼M primers in technical and biological triplicates. ABI Quantstudio three was used to run the qPCR. The PCR cycle were 95 Â°C for 3 min followed by 35 cycles of 95 Â°C for 10 s and 60 Â°C for 30 s. Gene expression was normalized to <italic>ActB</italic> followed by calculating relative expression using the 2<sup>-(ÎÎCt)</sup> method. The list of primers is found in <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>RT-PCR primer sequences.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Gene symbol</th><th align="left" valign="top">Forward</th><th align="left" valign="top">Reverse</th></tr></thead><tbody><tr><td align="left" valign="top"><italic>Slc1a5</italic></td><td align="left" valign="top">TGGAGATGAAAGACGTCCGC</td><td align="left" valign="top">CAGGCAGGCTGACACTGGAT</td></tr><tr><td align="left" valign="top"><italic>Î²-actin</italic></td><td align="left" valign="top">AGATGTGGATCAGCAAGCAG</td><td align="left" valign="top">GCGCAAGTTAGGTTTTGTCA</td></tr><tr><td align="left" valign="top"><italic>Akp2</italic></td><td align="left" valign="top">CCAACTCTTTTGTGCCAGAGA</td><td align="left" valign="top">GGCTACATTGGTGTTGAGCTTTT</td></tr><tr><td align="left" valign="top"><italic>Ibsp</italic></td><td align="left" valign="top">CAGAGGAGGCAAGCGTCACT</td><td align="left" valign="top">GCTGTCTGGGTGCCAACACT</td></tr><tr><td align="left" valign="top"><italic>Sp7</italic></td><td align="left" valign="top">CCTTCTCAAGCACCAATGG</td><td align="left" valign="top">AAGGGTGGGTAGTCATTTGCATA</td></tr><tr><td align="left" valign="top"><italic>Runx2</italic></td><td align="left" valign="top">CCAACCGAGTCATTTAAGGCT</td><td align="left" valign="top">GCTCACGTCGCTCATCTTG</td></tr><tr><td align="left" valign="top"><italic>Bglap</italic></td><td align="left" valign="top">CAGCGGCCCTGAGTCTGA</td><td align="left" valign="top">GCCGGAGTCTGTTCACTACCTTA</td></tr><tr><td align="left" valign="top"><italic>Asns</italic></td><td align="left" valign="top">CAAGGAGCCCAAGTTCAGTAT</td><td align="left" valign="top">GGCTGTCCTCCAGCCAAT</td></tr></tbody></table></table-wrap></sec><sec id="s4-5"><title>Western blotting</title><p>To isolate protein, cells were scraped, or bones were pulverized in RIPA lysis buffer (50 mM Tris (pH 7.4), 15 mM NaCl, 0.5% NP-40) containing protease and phosphatase inhibitors (Roche). Protein concentration was measured using the BCA method and 10 Î¼g of the protein was run on 10 % polyacrylamide gel. The protein was then transferred to a nitrocellulose membrane which was blocked for 1 hour at room temperature with 5 % milk in TBST (TBS, 0.1 % Tween20). The blots were then incubated with primary antibodies raised against ASCT2/SLC1A5 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10621427">AB_10621427</ext-link>, 1:1000), Eif2Î± (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10692650">AB_10692650</ext-link>), pSer51 Eif2Î± (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2096481">AB_2096481</ext-link>) pSer240/244 S6rp (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331682">AB_331682</ext-link>, 1:1000), S6rp (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331355">AB_331355</ext-link>, 1:1000), Î±-tubulin (RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2619646">AB_2619646</ext-link>, 1:1000), or Î²-actin (RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330288">AB_330288</ext-link>, 1:2000) overnight at 4 C. On day 2, the membranes were washed three times 5 min each with TBST and incubated with appropriate secondary antibody HRP goat anti-rabbit (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2099233">AB_2099233</ext-link>) or HRP anti-mouse (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330924">AB_330924</ext-link>) in 5 % milk in TBST for 1 hr at room temperature. The membranes were again washed three times with TBST and developed using clarity ECL substrate (Biorad) or super signal West Femto ECL.</p></sec><sec id="s4-6"><title>EdU incorporation and annexin V assay</title><p>5000 cells/well were seeded in a 96 well plate for 12â16 hr after which the cells were incubated with 10 Î¼M EdU (5-ethynyl-2â-deoxyuridine) for 6 hr. EdU incorporation was performed using the instructions provided in the Click-iT EdU Cell Proliferation Imaging Kit (Invitrogen, C10337). EdU incorporation was also analyzed using Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit (Invitrogen, C10420) after 24 hr incubation with 10 Î¼M EdU. The cells were then trypsinized, permeabilized and stained as per kit instructions. Cell viability assay was performed using the Apoptosis Assay Kit (Cat# 22837).</p></sec><sec id="s4-7"><title>Skeletal prep</title><p>Timed pregnant females were euthanized, and pups were harvested at E14.5, E15.5, and P0. The embryos were skinned, eviscerated and dehydrated in 95 % ethanol overnight. The mice were transferred to acetone for another night to dissolve fat tissue. After which, the tissue was stained with Alcian blue 8 GX (0.03%, m/v in 70 % ethanol) and Alizarin red S (0.005%, m/v in dH<sub>2</sub>O) solution containing 10 % acetic acid and 80 % ethanol. The stained skeletons were cleared in 1 % KOH followed by a gradient of glycerol.</p></sec><sec id="s4-8"><title>Histology, immunofluorescence, and in situ hybridization</title><p>Limbs and skulls from E15.5, E16.5, and P0 were harvested skinned and fixed overnight in 4 % PFA (paraformaldehyde). Limbs from E16.5 and P0 were decalcified in 14 % EDTA overnight, followed by transferring them to 30 % sucrose for frozen embedding in OCT and 70 % ethanol for paraffin embedding. Paraffin embedded blocks were sectioned at 5 Î¼M thickness and utilized for Alcian blue and picro-sirius, von Kossa and alcian blue using standard protocols.</p><p>Immunofluorescence was performed on 10 Î¼M frozen sections brought to room temperature and incubated with 3 % H<sub>2</sub>O<sub>2</sub> for 10 min. The sections were then incubated with 1.5 % goat serum in PBST (PBS with 0.1 % Tween20) at room temperature for 1 hr. The sections were then incubated overnight in primary antibodies COL1A1 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_638601">AB_638601</ext-link>,1:200), OSX (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2194492">AB_2194492</ext-link> 1:500,), PCNA (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2160343">AB_2160343</ext-link>,1:500) diluted in 1.5 % goat serum in PBST. On day 2, the sections were washed three times with PBST for 5 min each and incubated with goat anti-mouse 568 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_141359">AB_141359</ext-link>, 1:1000) for COL1A1 and goat anti-Rabbit 568 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_143157">AB_143157</ext-link>, 1:1000) for OSX and PCNA for 30 min at room temperature. The sections were then mounted with DAPI and imaged. COL1A1 intensity was measured in the <italic>Sp7<sup>GFP</sup></italic>-positive region. OSX, <italic>Sp7<sup>GFP</sup></italic> copositive cells were counted using Image J.</p><p>In situ hybridization was performed on 10 Î¼M frozen sections. The sections were fixed with 4 % PFA for 10 min at room temperature followed by 10 min in acetylation solution (1.3 % triethanolamine, 0.175 % HCl, 0.375 % acetic anhydride in dH<sub>2</sub>O). The sections were then washed and incubated with hybridization buffer (50 % formamide (deionized), 5 X SSC, pH 4.5 (use citric acid to pH), 1 % SDS, 50 Î¼g/mL yeast tRNA, 50 Î¼g/mL heparin) for 2 hr in a humidified chamber. The excess hybridization buffer was removed and prewarmed probe diluted 1:10 was added to the slides, covered with parafilm and incubated at 60 C overnight. The slides were immersed in 5 X SSC to remove the parafilm and washed twice with 0.2 X SSC for 30 min at 60 C. After an additional wash at room temperature with 0.2 X SSC the slides were transferred to NTT (0.15 M NaCl, 0.1 M tris-Cl pH 7.5, 0.1 % tween 20) for 10 min at room temperature. The slides were blocked with blocking buffer (5 % heat inactivated sheep serum, 2 % blocking reagent/NTT) for 2 hr, followed by incubation with anti-Dig AP antibody diluted at 1:4000 in the blocking buffer overnight at 4 C. On the third day, the slides were washed with NTT on rotator three times for 30 min each, followed by 3 5 min washes with NTTML (0.15 M NaCl, 0.1 M tris pH 9.5, 50 mM MgCl<sub>2</sub>,2mM Levamisole, 0.1 % tween 20). The slides were then incubated with prewarmed AP substrate BM purple (ROCHE) at 37 C and monitored for desired staining. After staining was achieved the slides were rinsed in PBS 3 times for 5 min each. The slides were fixed in 0.2 % glutaraldehyde in 4 % PFA overnight, the slides were then mounted with glycergel and imaged.</p></sec><sec id="s4-9"><title>Micro computed tomography (uCT)</title><p>Micro computed tomography (ÂµCT) (VivaCT80, Scanco Medical AG) was used for three-dimensional reconstruction and analysis of bone parameters. Calvariae were harvested from either newborn mice or 2-month-old mice. All muscle and extemporaneous tissue were removed and the isolated calvariae were washed in PBS, fixed overnight in 10%NBF and dehydrated in 70 % ethanol. The calvariae were immobilized in 2 % agarose in PBS for scanning. A fixed volume surrounding the skull was used for 3D reconstructions. In newborn calvariae, bone volume was quantified from a fixed number of slices in the occipital lobe. The threshold was set at 280. For quantification of bone mass in the long bone, 2-month-old femurs were isolated, fixed, immobilized, and scanned. Bone parameters were quantified from 200 slices directly underneath the growth plate with the threshold set at 320.</p><p>Mass spectrometry and metabolic tracing cOB isolated from RosaCas9 homozygous P3 pups were cultured in 6 cm plates and treated as indicated. Cells were incubated with 2 mM [U-<sup>13</sup>C]glutamine, 2 mM [Î±â15N]glutamine, 0.33 mM [U-<sup>13</sup>C]Asparagine and 0.33 mM [Î±â15N] Asparagine for either 24 or 72 hours as indicated. Cells treated for 24 hr were washed with cold PBS and isolated three times with â80 Â°C methanol on dry ice in Eppendorf tubes containing 20 nM norvaline, which is an internal standard. The extracts were vortexed and centrifuged at 12,000 RPM for 15 min. The supernatant was completely dried with N<sub>2</sub> gas. The dried residue was resuspended in 25 Î¼l methoxylamine hydrochloride (2 % MOX in pyridine) and incubated for 90 min at 40 Â°C on a heat block. After the incubation, the samples were spun at maximum speed for 2 min and 35 Î¼l of MTBSTFA + 1 % TBDMS was added followed by a 30 min incubation at 60 Â°C. The samples were centrifuged at 12,000 RPM for 5 minutes and the supernatant was transferred to GC vials for GC-MS analysis. For the experiments tracing labeled amino acids into protein, cells were incubated with 2 mM [U-<sup>13</sup>C]glutamine, 2 mM [Î±â15N]glutamine, 0.33 mM [U-<sup>13</sup>C]Asparagine or 0.33 mM [Î±â15N] Asparagine for 72 hours. Cells were isolated in 1 ml 1 M PCA and centrifuged for 10 min to precipitate the protein. The precipitate was washed twice with 1 ml 70 % ethanol after which 20 nM norvaline was added to the samples. The protein was hydrolyzed with 1 ml 6 M HCl at 110 Â°C for 18 hr. The samples were cooled and 1 ml chloroform was added and vortexed to remove hydrophobic metabolites. The isolates were centrifuged for 10 minutes and 100 Î¼l of the supernatant was dried with N<sub>2</sub> gas until dry, 50 Î¼l of MTBSTFA + 1 % TBDMS was added followed by a 30 min incubation at 60 Â°C. The samples were transferred to GC vials for GC-MS analysis.</p></sec><sec id="s4-10"><title>tRNA aminoacylation assay</title><p>The method is adapted from two recent reports (<xref ref-type="bibr" rid="bib32">Loayza-Puch et al., 2016</xref>). Purified RNA was resuspended in 30 mM NaOAc/HOAc (pH 4.5). RNA was divided into two parts (2Âµ g each): one was oxidized with 50 mM NaIO<sub>4</sub> in 100 mM NaOAc/HOAc (pH 4.5) and the other was treated with 50 mM NaCl in NaOAc/HOAc (pH 4.5) for 15 min at room temperature. Samples were quenched with 100 mM glucose for 5 min at room temperature, followed by desaltation using G50 columns and precipitation using ethanol. tRNA was then deacylated in 50 mM Tris-HCl (pH 9) for 30 min at 37Â°C, followed by another ethanol precipitation. RNA (400 ng) was then ligated the 3â²adaptor.</p><p>(5â²-/5rApp/<named-content content-type="sequence">TGGAATTCTCGGGTGCCAAGG</named-content>/3ddC/â3â²) using T4 RNA ligase 2(NEB) for 4 hr at 37 Â°C. 1Âµ g RNA was then reverse transcribed using SuperScript III first strand synthesis system with the primer (<named-content content-type="sequence">GCCTTGGCACCCGAGAATTCCA</named-content>) following the manufacturerâs instruction.</p></sec><sec id="s4-11"><title>Quantification and statistical analysis</title><p>All statistics were performed in Graphpad six software. In cell culture studies, statistical significance was determined by an unpaired two-tailed Studentâs <italic>t</italic>-test or one-way Anova. For uCT statistical significance was determine by a paired two-tailed Studentâs <italic>t</italic>-test comparing paired littermate controls. All quantifications are represented as mean Â± standard deviation. A p value of less than 0.05 is considered statistically significant. All experiments were performed with n â¥ 3 biological replicates. The sample size and statistical analysis are noted in the Figure legends.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation, Writing â review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Writing â review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing â review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing â review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Funding acquisition, Investigation, Project administration, Writing â original draft, Writing â review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal procedures were approved (APN 2020-102999) by the Animal Studies Committees at Duke University and the University of Texas Southwestern Medical Center at Dallas.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-71595-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank Drs. Vishal Patel and Guoli Hu for critical comments on this manuscript. This work was supported by National Institute of Health R01 grants (AR076325 and AR071967) to CMK.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamson</surname><given-names>LF</given-names></name><name><surname>Ingbar</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="1967">1967</year><article-title>Further studies of amino acid transport by embryonic chick bone</article-title><source>The Journal of Biological Chemistry</source><volume>242</volume><fpage>2646</fpage><lpage>2652</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)99619-5</pub-id><pub-id pub-id-type="pmid">6027240</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhutia</surname><given-names>YD</given-names></name><name><surname>Babu</surname><given-names>E</given-names></name><name><surname>Ramachandran</surname><given-names>S</given-names></name><name><surname>Ganapathy</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Amino Acid transporters in cancer and their relevance to âglutamine addictionâ: novel targets for the design of a new class of anticancer drugs</article-title><source>Cancer Research</source><volume>75</volume><fpage>1782</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3745</pub-id><pub-id pub-id-type="pmid">25855379</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birsoy</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>WW</given-names></name><name><surname>Freinkman</surname><given-names>E</given-names></name><name><surname>Abu-Remaileh</surname><given-names>M</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis</article-title><source>Cell</source><volume>162</volume><fpage>540</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.016</pub-id><pub-id pub-id-type="pmid">26232224</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BrÃ¶er</surname><given-names>A</given-names></name><name><surname>Brookes</surname><given-names>N</given-names></name><name><surname>Ganapathy</surname><given-names>V</given-names></name><name><surname>Dimmer</surname><given-names>KS</given-names></name><name><surname>Wagner</surname><given-names>CA</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name><name><surname>BrÃ¶er</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The astroglial ASCT2 amino acid transporter as a mediator of glutamine efflux</article-title><source>Journal of Neurochemistry</source><volume>73</volume><fpage>2184</fpage><lpage>2194</lpage><pub-id pub-id-type="pmid">10537079</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BrÃ¶er</surname><given-names>A</given-names></name><name><surname>Rahimi</surname><given-names>F</given-names></name><name><surname>BrÃ¶er</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>13194</fpage><lpage>13205</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.700534</pub-id><pub-id pub-id-type="pmid">27129276</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>X</given-names></name><name><surname>Esen</surname><given-names>E</given-names></name><name><surname>Joeng</surname><given-names>KS</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Arbeit</surname><given-names>JM</given-names></name><name><surname>RÃ¼egg</surname><given-names>MA</given-names></name><name><surname>Hall</surname><given-names>MN</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Long</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>WNT7B promotes bone formation in part through mTORC1</article-title><source>PLOS Genetics</source><volume>10</volume><elocation-id>e1004145</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004145</pub-id><pub-id pub-id-type="pmid">24497849</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>R</given-names></name><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Daikhin</surname><given-names>E</given-names></name><name><surname>Nissim</surname><given-names>I</given-names></name><name><surname>Yudkoff</surname><given-names>M</given-names></name><name><surname>Wehrli</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis</article-title><source>PNAS</source><volume>104</volume><fpage>19345</fpage><lpage>19350</lpage><pub-id pub-id-type="doi">10.1073/pnas.0709747104</pub-id><pub-id pub-id-type="pmid">18032601</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>R. J</given-names></name><name><surname>Lum</surname><given-names>JJ</given-names></name><name><surname>Hatzivassiliou</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The biology of cancer: metabolic reprogramming fuels cell growth and proliferation</article-title><source>Cell Metabolism</source><volume>7</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.002</pub-id><pub-id pub-id-type="pmid">18177721</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eagle</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1955">1955</year><article-title>Nutrition needs of mammalian cells in tissue culture</article-title><source>Science</source><volume>122</volume><fpage>501</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1126/science.122.3168.501</pub-id><pub-id pub-id-type="pmid">13255879</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elefteriou</surname><given-names>F</given-names></name><name><surname>Benson</surname><given-names>MD</given-names></name><name><surname>Sowa</surname><given-names>H</given-names></name><name><surname>Starbuck</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ron</surname><given-names>D</given-names></name><name><surname>Parada</surname><given-names>LF</given-names></name><name><surname>Karsenty</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae</article-title><source>Cell Metabolism</source><volume>4</volume><fpage>441</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2006.10.010</pub-id><pub-id pub-id-type="pmid">17141628</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finerman</surname><given-names>GA</given-names></name><name><surname>Rosenberg</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="1966">1966</year><article-title>Amino acid transport in bone Evidence for separate transport systems for neutral amino and imino acids</article-title><source>The Journal of Biological Chemistry</source><volume>241</volume><fpage>1487</fpage><lpage>1493</lpage><pub-id pub-id-type="pmid">5946610</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitter</surname><given-names>S</given-names></name><name><surname>Matthews</surname><given-names>MP</given-names></name><name><surname>Martin</surname><given-names>SK</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Ooi</surname><given-names>SS</given-names></name><name><surname>Walkley</surname><given-names>CR</given-names></name><name><surname>Codrington</surname><given-names>JD</given-names></name><name><surname>Ruegg</surname><given-names>MA</given-names></name><name><surname>Hall</surname><given-names>MN</given-names></name><name><surname>Proud</surname><given-names>CG</given-names></name><name><surname>Gronthos</surname><given-names>S</given-names></name><name><surname>Zannettino</surname><given-names>ACW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mTORC1 Plays an Important Role in Skeletal Development by Controlling Preosteoblast Differentiation</article-title><source>Molecular and Cellular Biology</source><volume>37</volume><elocation-id>e00668-16</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00668-16</pub-id><pub-id pub-id-type="pmid">28069737</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>B</given-names></name><name><surname>Nichols</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1964">1964</year><article-title>Metabolic Studies of Bone in Vitro</article-title><source>Journal of Biological Chemistry</source><volume>239</volume><fpage>1261</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)91421-3</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Bermudez</surname><given-names>J</given-names></name><name><surname>Baudrier</surname><given-names>L</given-names></name><name><surname>La</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>XG</given-names></name><name><surname>Fidelin</surname><given-names>J</given-names></name><name><surname>Sviderskiy</surname><given-names>VO</given-names></name><name><surname>Papagiannakopoulos</surname><given-names>T</given-names></name><name><surname>Molina</surname><given-names>H</given-names></name><name><surname>Snuderl</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>CA</given-names></name><name><surname>Possemato</surname><given-names>RL</given-names></name><name><surname>Birsoy</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours</article-title><source>Nature Cell Biology</source><volume>20</volume><fpage>775</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0118-z</pub-id><pub-id pub-id-type="pmid">29941933</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>CR</given-names></name><name><surname>Wallace</surname><given-names>M</given-names></name><name><surname>Divakaruni</surname><given-names>AS</given-names></name><name><surname>Phillips</surname><given-names>SA</given-names></name><name><surname>Murphy</surname><given-names>AN</given-names></name><name><surname>Ciaraldi</surname><given-names>TP</given-names></name><name><surname>Metallo</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Branched-chain amino acid catabolism fuels adipocyte differentiation and lipogenesis</article-title><source>Nature Chemical Biology</source><volume>12</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1961</pub-id><pub-id pub-id-type="pmid">26571352</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guntur</surname><given-names>AR</given-names></name><name><surname>Le</surname><given-names>PT</given-names></name><name><surname>Farber</surname><given-names>CR</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bioenergetics during calvarial osteoblast differentiation reflect strain differences in bone mass</article-title><source>Endocrinology</source><volume>155</volume><fpage>1589</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1210/en.2013-1974</pub-id><pub-id pub-id-type="pmid">24437492</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>TJ</given-names></name><name><surname>Downing</surname><given-names>SJ</given-names></name><name><surname>Phang</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>sulin effect on amino acid transport in bone</article-title><source>Biochimica et Biophysica Acta</source><volume>184</volume><fpage>675</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/0304-4165(69)90292-x</pub-id><pub-id pub-id-type="pmid">5821033</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassanein</surname><given-names>M</given-names></name><name><surname>Hoeksema</surname><given-names>MD</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>BK</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Clark</surname><given-names>JE</given-names></name><name><surname>Alborn</surname><given-names>WE</given-names></name><name><surname>Eisenberg</surname><given-names>R</given-names></name><name><surname>Massion</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival</article-title><source>Clinical Cancer Research</source><volume>19</volume><fpage>560</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2334</pub-id><pub-id pub-id-type="pmid">23213057</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosios</surname><given-names>AM</given-names></name><name><surname>Hecht</surname><given-names>VC</given-names></name><name><surname>Danai</surname><given-names>LV</given-names></name><name><surname>Johnson</surname><given-names>MO</given-names></name><name><surname>Rathmell</surname><given-names>JC</given-names></name><name><surname>Steinhauser</surname><given-names>ML</given-names></name><name><surname>Manalis</surname><given-names>SR</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells</article-title><source>Developmental Cell</source><volume>36</volume><fpage>540</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2016.02.012</pub-id><pub-id pub-id-type="pmid">26954548</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>YJ</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Long</surname><given-names>F</given-names></name><name><surname>Karner</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Amino Acid Sensor Eif2ak4/GCN2 Is Required for Proliferation of Osteoblast Progenitors in Mice</article-title><source>Journal of Bone and Mineral Research</source><volume>35</volume><fpage>2004</fpage><lpage>2014</lpage><pub-id pub-id-type="doi">10.1002/jbmr.4091</pub-id><pub-id pub-id-type="pmid">32453500</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>CL</given-names></name><name><surname>Stevens</surname><given-names>BM</given-names></name><name><surname>DâAlessandro</surname><given-names>A</given-names></name><name><surname>Reisz</surname><given-names>JA</given-names></name><name><surname>Culp-Hill</surname><given-names>R</given-names></name><name><surname>Nemkov</surname><given-names>T</given-names></name><name><surname>Pei</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Adane</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Krug</surname><given-names>A</given-names></name><name><surname>Reinhold</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>DeGregori</surname><given-names>J</given-names></name><name><surname>Pollyea</surname><given-names>DA</given-names></name><name><surname>Jordan</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells</article-title><source>Cancer Cell</source><volume>34</volume><fpage>724</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.10.005</pub-id><pub-id pub-id-type="pmid">30423294</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>CL</given-names></name><name><surname>Stevens</surname><given-names>BM</given-names></name><name><surname>DâAlessandro</surname><given-names>A</given-names></name><name><surname>Reisz</surname><given-names>JA</given-names></name><name><surname>Culp-Hill</surname><given-names>R</given-names></name><name><surname>Nemkov</surname><given-names>T</given-names></name><name><surname>Pei</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Adane</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Krug</surname><given-names>A</given-names></name><name><surname>Reinhold</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>DeGregori</surname><given-names>J</given-names></name><name><surname>Pollyea</surname><given-names>DA</given-names></name><name><surname>Jordan</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells</article-title><source>Cancer Cell</source><volume>35</volume><fpage>333</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.01.013</pub-id><pub-id pub-id-type="pmid">30753831</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karner</surname><given-names>CM</given-names></name><name><surname>Esen</surname><given-names>E</given-names></name><name><surname>Okunade</surname><given-names>AL</given-names></name><name><surname>Patterson</surname><given-names>BW</given-names></name><name><surname>Long</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>creased glutamine catabolism mediates bone anabolism in response to WNT signaling</article-title><source>The Journal of Clinical Investigation</source><volume>125</volume><fpage>551</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1172/JCI78470</pub-id><pub-id pub-id-type="pmid">25562323</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karner</surname><given-names>CM</given-names></name><name><surname>Long</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wnt signaling and cellular metabolism in osteoblasts</article-title><source>Cellular and Molecular Life Sciences</source><volume>74</volume><fpage>1649</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2425-5</pub-id><pub-id pub-id-type="pmid">27888287</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karner</surname><given-names>CM</given-names></name><name><surname>Long</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Glucose metabolism in bone</article-title><source>Bone</source><volume>115</volume><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2017.08.008</pub-id><pub-id pub-id-type="pmid">28843700</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyokawa</surname><given-names>H</given-names></name><name><surname>Kineman</surname><given-names>RD</given-names></name><name><surname>Manova-Todorova</surname><given-names>KO</given-names></name><name><surname>Soares</surname><given-names>VC</given-names></name><name><surname>Hoffman</surname><given-names>ES</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Khanam</surname><given-names>D</given-names></name><name><surname>Hayday</surname><given-names>AC</given-names></name><name><surname>Frohman</surname><given-names>LA</given-names></name><name><surname>Koff</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1</article-title><source>Cell</source><volume>85</volume><fpage>721</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81238-6</pub-id><pub-id pub-id-type="pmid">8646780</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krall</surname><given-names>AS</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Braas</surname><given-names>D</given-names></name><name><surname>Christofk</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11457</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11457</pub-id><pub-id pub-id-type="pmid">27126896</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>MariÃ±o</surname><given-names>G</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Autophagy and the integrated stress response</article-title><source>Molecular Cell</source><volume>40</volume><fpage>280</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.09.023</pub-id><pub-id pub-id-type="pmid">20965422</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Guntur</surname><given-names>AR</given-names></name><name><surname>Long</surname><given-names>F</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Energy Metabolism of the Osteoblast: Implications for Osteoporosis</article-title><source>Endocrine Reviews</source><volume>38</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1210/er.2017-00064</pub-id><pub-id pub-id-type="pmid">28472361</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Nissim</surname><given-names>I</given-names></name><name><surname>Long</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Malic Enzyme Couples Mitochondria with Aerobic Glycolysis in Osteoblasts</article-title><source>Cell Reports</source><volume>32</volume><elocation-id>108108</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108108</pub-id><pub-id pub-id-type="pmid">32905773</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The role of ASCT2 in cancer: A review</article-title><source>European Journal of Pharmacology</source><volume>837</volume><fpage>81</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2018.07.007</pub-id><pub-id pub-id-type="pmid">30025811</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loayza-Puch</surname><given-names>F</given-names></name><name><surname>Rooijers</surname><given-names>K</given-names></name><name><surname>Buil</surname><given-names>LCM</given-names></name><name><surname>Zijlstra</surname><given-names>J</given-names></name><name><surname>Oude Vrielink</surname><given-names>JF</given-names></name><name><surname>Lopes</surname><given-names>R</given-names></name><name><surname>Ugalde</surname><given-names>AP</given-names></name><name><surname>van Breugel</surname><given-names>P</given-names></name><name><surname>Hofland</surname><given-names>I</given-names></name><name><surname>Wesseling</surname><given-names>J</given-names></name><name><surname>van Tellingen</surname><given-names>O</given-names></name><name><surname>Bex</surname><given-names>A</given-names></name><name><surname>Agami</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tumour-specific proline vulnerability uncovered by differential ribosome codon reading</article-title><source>Nature</source><volume>530</volume><fpage>490</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1038/nature16982</pub-id><pub-id pub-id-type="pmid">26878238</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Kunkel</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>JM</given-names></name><name><surname>Behringer</surname><given-names>RR</given-names></name><name><surname>de Crombrugghe</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation</article-title><source>Cell</source><volume>108</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(01)00622-5</pub-id><pub-id pub-id-type="pmid">11792318</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakaya</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>J-H</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Blonska</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>S-C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>flammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation</article-title><source>Immunity</source><volume>40</volume><fpage>692</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.04.007</pub-id><pub-id pub-id-type="pmid">24792914</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicklin</surname><given-names>P</given-names></name><name><surname>Bergman</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Triantafellow</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Nyfeler</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Hild</surname><given-names>M</given-names></name><name><surname>Kung</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>MacKeigan</surname><given-names>JP</given-names></name><name><surname>Porter</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>YK</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Finan</surname><given-names>PM</given-names></name><name><surname>Murphy</surname><given-names>LO</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Bidirectional transport of amino acids regulates mTOR and autophagy</article-title><source>Cell</source><volume>136</volume><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.11.044</pub-id><pub-id pub-id-type="pmid">19203585</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ornitz</surname><given-names>DM</given-names></name><name><surname>Marie</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease</article-title><source>Genes &amp; Development</source><volume>16</volume><fpage>1446</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1101/gad.990702</pub-id><pub-id pub-id-type="pmid">12080084</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>F</given-names></name><name><surname>Thornell</surname><given-names>AP</given-names></name><name><surname>Crompton</surname><given-names>T</given-names></name><name><surname>Denzel</surname><given-names>A</given-names></name><name><surname>Gilmour</surname><given-names>KC</given-names></name><name><surname>Rosewell</surname><given-names>IR</given-names></name><name><surname>Stamp</surname><given-names>GW</given-names></name><name><surname>Beddington</surname><given-names>RS</given-names></name><name><surname>Mundlos</surname><given-names>S</given-names></name><name><surname>Olsen</surname><given-names>BR</given-names></name><name><surname>Selby</surname><given-names>PB</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development</article-title><source>Cell</source><volume>89</volume><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)80259-7</pub-id><pub-id pub-id-type="pmid">9182764</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pakos-Zebrucka</surname><given-names>K</given-names></name><name><surname>Koryga</surname><given-names>I</given-names></name><name><surname>Mnich</surname><given-names>K</given-names></name><name><surname>Ljujic</surname><given-names>M</given-names></name><name><surname>Samali</surname><given-names>A</given-names></name><name><surname>Gorman</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The integrated stress response</article-title><source>EMBO Reports</source><volume>17</volume><fpage>1374</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.15252/embr.201642195</pub-id><pub-id pub-id-type="pmid">27629041</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palm</surname><given-names>W</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nutrient acquisition strategies of mammalian cells</article-title><source>Nature</source><volume>546</volume><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/nature22379</pub-id><pub-id pub-id-type="pmid">28593971</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardee</surname><given-names>AB</given-names></name><name><surname>Dubrow</surname><given-names>R</given-names></name><name><surname>Hamlin</surname><given-names>JL</given-names></name><name><surname>Kletzien</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Animal cell cycle</article-title><source>Annual Review of Biochemistry</source><volume>47</volume><fpage>715</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.47.070178.003435</pub-id><pub-id pub-id-type="pmid">354504</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlova</surname><given-names>NN</given-names></name><name><surname>Hui</surname><given-names>S</given-names></name><name><surname>Ghergurovich</surname><given-names>JM</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Intlekofer</surname><given-names>AM</given-names></name><name><surname>White</surname><given-names>RM</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid</article-title><source>Cell Metabolism</source><volume>27</volume><fpage>428</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.12.006</pub-id><pub-id pub-id-type="pmid">29337136</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phang</surname><given-names>JM</given-names></name><name><surname>Downing</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>Amino acid transport in bone: stimulation by cyclic AMP</article-title><source>The American Journal of Physiology</source><volume>224</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1152/ajplegacy.1973.224.1.191</pub-id><pub-id pub-id-type="pmid">4345737</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quarles</surname><given-names>LD</given-names></name><name><surname>Yohay</surname><given-names>DA</given-names></name><name><surname>Lever</surname><given-names>LW</given-names></name><name><surname>Caton</surname><given-names>R</given-names></name><name><surname>Wenstrup</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development</article-title><source>Journal of Bone and Mineral Research</source><volume>7</volume><fpage>683</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1002/jbmr.5650070613</pub-id><pub-id pub-id-type="pmid">1414487</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rached</surname><given-names>M-T</given-names></name><name><surname>Kode</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Yoshikawa</surname><given-names>Y</given-names></name><name><surname>Paik</surname><given-names>J-H</given-names></name><name><surname>Depinho</surname><given-names>RA</given-names></name><name><surname>Kousteni</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts</article-title><source>Cell Metabolism</source><volume>11</volume><fpage>147</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2010.01.001</pub-id><pub-id pub-id-type="pmid">20142102</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Yue</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>D</given-names></name><name><surname>Xiu</surname><given-names>R</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Qing</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation</article-title><source>The Journal of Pathology</source><volume>235</volume><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1002/path.4429</pub-id><pub-id pub-id-type="pmid">25142020</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riddle</surname><given-names>RC</given-names></name><name><surname>Clemens</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Bone Cell Bioenergetics and Skeletal Energy Homeostasis</article-title><source>Physiological Reviews</source><volume>97</volume><fpage>667</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1152/physrev.00022.2016</pub-id><pub-id pub-id-type="pmid">28202599</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodda</surname><given-names>SJ</given-names></name><name><surname>McMahon</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors</article-title><source>Development</source><volume>133</volume><fpage>3231</fpage><lpage>3244</lpage><pub-id pub-id-type="doi">10.1242/dev.02480</pub-id><pub-id pub-id-type="pmid">16854976</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte</surname><given-names>ML</given-names></name><name><surname>Fu</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>ST</given-names></name><name><surname>Kondo</surname><given-names>J</given-names></name><name><surname>Coffey</surname><given-names>RJ</given-names></name><name><surname>Johnson</surname><given-names>MO</given-names></name><name><surname>Rathmell</surname><given-names>JC</given-names></name><name><surname>Sharick</surname><given-names>JT</given-names></name><name><surname>Skala</surname><given-names>MC</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name><name><surname>Berlin</surname><given-names>J</given-names></name><name><surname>Washington</surname><given-names>MK</given-names></name><name><surname>Nickels</surname><given-names>ML</given-names></name><name><surname>Manning</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models</article-title><source>Nature Medicine</source><volume>24</volume><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1038/nm.4464</pub-id><pub-id pub-id-type="pmid">29334372</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scopelliti</surname><given-names>AJ</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><name><surname>Vandenberg</surname><given-names>RJ</given-names></name><name><surname>Boudker</surname><given-names>O</given-names></name><name><surname>Ryan</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02444-w</pub-id><pub-id pub-id-type="pmid">29295993</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Long</surname><given-names>F</given-names></name><name><surname>Karner</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Biphasic regulation of glutamine consumption by WNT during osteoblast differentiation</article-title><source>Journal of Cell Science</source><volume>134</volume><elocation-id>jcs251645</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.251645</pub-id><pub-id pub-id-type="pmid">33262314</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singha</surname><given-names>UK</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells</article-title><source>Journal of Cellular Biochemistry</source><volume>103</volume><fpage>434</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1002/jcb.21411</pub-id><pub-id pub-id-type="pmid">17516572</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stegen</surname><given-names>S</given-names></name><name><surname>Devignes</surname><given-names>C-S</given-names></name><name><surname>Torrekens</surname><given-names>S</given-names></name><name><surname>Van Looveren</surname><given-names>R</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Carmeliet</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Glutamine Metabolism in Osteoprogenitors Is Required for Bone Mass Accrual and PTH-Induced Bone Anabolism in Male Mice</article-title><source>Journal of Bone and Mineral Research</source><volume>36</volume><fpage>604</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1002/jbmr.4219</pub-id><pub-id pub-id-type="pmid">33253422</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>GS</given-names></name><name><surname>Lian</surname><given-names>JB</given-names></name><name><surname>Owen</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation</article-title><source>FASEB Journal</source><volume>4</volume><fpage>3111</fpage><lpage>3123</lpage><pub-id pub-id-type="doi">10.1096/fasebj.4.13.2210157</pub-id><pub-id pub-id-type="pmid">2210157</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>GS</given-names></name><name><surname>Lian</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype</article-title><source>Endocrine Reviews</source><volume>14</volume><fpage>424</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1210/edrv-14-4-424</pub-id><pub-id pub-id-type="pmid">8223340</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>LB</given-names></name><name><surname>Gui</surname><given-names>DY</given-names></name><name><surname>Hosios</surname><given-names>AM</given-names></name><name><surname>Bush</surname><given-names>LN</given-names></name><name><surname>Freinkman</surname><given-names>E</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells</article-title><source>Cell</source><volume>162</volume><fpage>552</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.017</pub-id><pub-id pub-id-type="pmid">26232225</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonna</surname><given-names>EA</given-names></name><name><surname>Cronkite</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="1961">1961</year><article-title>Autoradiographic studies of cell proliferation in the periosteum of intact and fractured femora of mice utilizing DNA labeling with H3-thymidine</article-title><source>Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine</source><volume>107</volume><fpage>719</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.3181/00379727-107-26733</pub-id><pub-id pub-id-type="pmid">13921864</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsunomiya-Tate</surname><given-names>N</given-names></name><name><surname>Endou</surname><given-names>H</given-names></name><name><surname>Kanai</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter</article-title><source>The Journal of Biological Chemistry</source><volume>271</volume><fpage>14883</fpage><lpage>14890</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.25.14883</pub-id><pub-id pub-id-type="pmid">8662767</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Geldermalsen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Nagarajah</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>AD</given-names></name><name><surname>Thoeng</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Ritchie</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Bailey</surname><given-names>CG</given-names></name><name><surname>Deng</surname><given-names>N</given-names></name><name><surname>Harvey</surname><given-names>K</given-names></name><name><surname>Beith</surname><given-names>JM</given-names></name><name><surname>Selinger</surname><given-names>CI</given-names></name><name><surname>OâToole</surname><given-names>SA</given-names></name><name><surname>Rasko</surname><given-names>JEJ</given-names></name><name><surname>Holst</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer</article-title><source>Oncogene</source><volume>35</volume><fpage>3201</fpage><lpage>3208</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.381</pub-id><pub-id pub-id-type="pmid">26455325</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Understanding the Intersections between Metabolism and Cancer Biology</article-title><source>Cell</source><volume>168</volume><fpage>657</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.039</pub-id><pub-id pub-id-type="pmid">28187287</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Alexander</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Hammer</surname><given-names>R</given-names></name><name><surname>Cleaver</surname><given-names>O</given-names></name><name><surname>McKnight</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Dependence of mouse embryonic stem cells on threonine catabolism</article-title><source>Science</source><volume>325</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1126/science.1173288</pub-id><pub-id pub-id-type="pmid">19589965</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Beaumont</surname><given-names>KA</given-names></name><name><surname>Otte</surname><given-names>NJ</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><name><surname>Bailey</surname><given-names>CG</given-names></name><name><surname>van Geldermalsen</surname><given-names>M</given-names></name><name><surname>Sharp</surname><given-names>DM</given-names></name><name><surname>Tiffen</surname><given-names>JC</given-names></name><name><surname>Ryan</surname><given-names>RM</given-names></name><name><surname>Jormakka</surname><given-names>M</given-names></name><name><surname>Haass</surname><given-names>NK</given-names></name><name><surname>Rasko</surname><given-names>JEJ</given-names></name><name><surname>Holst</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting glutamine transport to suppress melanoma cell growth</article-title><source>Ternational Journal of Cancer</source><volume>135</volume><fpage>1060</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1002/ijc.28749</pub-id><pub-id pub-id-type="pmid">24531984</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Asparagine enhances LCK signalling to potentiate CD8+ T-cell activation and anti-tumour responses</article-title><source>Nature Cell Biology</source><volume>23</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1038/s41556-020-00615-4</pub-id><pub-id pub-id-type="pmid">33420490</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xian</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Pang</surname><given-names>L</given-names></name><name><surname>Lou</surname><given-names>M</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Qiu</surname><given-names>T</given-names></name><name><surname>Crane</surname><given-names>J</given-names></name><name><surname>Frassica</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Rodriguez</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells</article-title><source>Nature Medicine</source><volume>18</volume><fpage>1095</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1038/nm.2793</pub-id><pub-id pub-id-type="pmid">22729283</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Kumanova</surname><given-names>M</given-names></name><name><surname>Hart</surname><given-names>LS</given-names></name><name><surname>Sloane</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>De Panis</surname><given-names>DN</given-names></name><name><surname>Bobrovnikova-Marjon</surname><given-names>E</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name><name><surname>Ron</surname><given-names>D</given-names></name><name><surname>Koumenis</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation</article-title><source>The EMBO Journal</source><volume>29</volume><fpage>2082</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.1038/emboj.2010.81</pub-id><pub-id pub-id-type="pmid">20473272</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Effect of parathyroid hormone on amino acid transport by cultured neonatal mouse calvarial bone cells</article-title><source>Journal of Bone and Mineral Research</source><volume>3</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1002/jbmr.5650030214</pub-id><pub-id pub-id-type="pmid">2850726</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Newman</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Mirando</surname><given-names>AJ</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Knudsen</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>G-F</given-names></name><name><surname>Hilton</surname><given-names>MJ</given-names></name><name><surname>Karner</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Glutamine Metabolism Regulates Proliferation and Lineage Allocation in Skeletal Stem Cells</article-title><source>Cell Metabolism</source><volume>29</volume><fpage>966</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.01.016</pub-id><pub-id pub-id-type="pmid">30773468</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>McGrath</surname><given-names>BC</given-names></name><name><surname>Reinert</surname><given-names>J</given-names></name><name><surname>Olsen</surname><given-names>DS</given-names></name><name><surname>Lei</surname><given-names>L</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Wek</surname><given-names>SA</given-names></name><name><surname>Vattem</surname><given-names>KM</given-names></name><name><surname>Wek</surname><given-names>RC</given-names></name><name><surname>Kimball</surname><given-names>SR</given-names></name><name><surname>Jefferson</surname><given-names>LS</given-names></name><name><surname>Cavener</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The GCN2 eIF2alpha kinase is required for adaptation to amino acid deprivation in mice</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>6681</fpage><lpage>6688</lpage><pub-id pub-id-type="doi">10.1128/mcb.22.19.6681-6688.2002</pub-id><pub-id pub-id-type="pmid">12215525</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Venneti</surname><given-names>S</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name><name><surname>Bhinder</surname><given-names>B</given-names></name><name><surname>Djaballah</surname><given-names>H</given-names></name><name><surname>Kanai</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>EH</given-names></name><name><surname>Judkins</surname><given-names>AR</given-names></name><name><surname>Pawel</surname><given-names>B</given-names></name><name><surname>Baggs</surname><given-names>J</given-names></name><name><surname>Cherry</surname><given-names>S</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion</article-title><source>Molecular Cell</source><volume>56</volume><fpage>205</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.08.018</pub-id><pub-id pub-id-type="pmid">25242145</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71595.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schipani</surname><given-names>Ernestina</given-names></name><role>Reviewing Editor</role><aff><institution>University of Pennsylvania</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.06.23.449651">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.06.23.449651v1.full">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This is an important work that evaluates the role of ASCT2 transporter in amino acid metabolisms in osteoblasts. State of the art in vitro and in vivo methods are used to prove that ASCT2 plays an important role in bone cells and tissue to supply glutamine required for normal osteoblasts function and matrix biosynthesis. This work adds new knowledge of osteoblast metabolism.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;SLC1A5 provides glutamine and asparagine necessary for bone development in mice&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and Carlos Isales as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Reviewers all agree the study is interesting, but a series of critical issues were raised that need to be addressed by either performing additional experiments or clarifying their interpretation of the current results.</p><p>Please address concerns and comments point-by-point.</p><p>In particular, it is crucial to carefully discuss the novelty of the findings. In addition, it is critical to clarify whether the OSX-Cre driver used in the study is inducible.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Specific Comments:</p><p>1. The authors show that impairing the intracellular transport of glutamine and asparagine decreases the intracellular accumulation of metabolites of the TCA cycle such as citrate and Î±-ketoglutarate. Is mitochondrial respiration negatively affected in mutant osteoblasts? Are the mutant cells energy deficient?</p><p>2. Are the widening of the sutures and the delay of the osteogenic front still present in the flat bones of the skull in mutant mice postnatally?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. The authors propose that inactivation of SLC1A5 affects osteoblast differentiation. While matrix mineralization is clearly decreased, it is not fully clear whether ALP staining is affected to the same extent using the different in vitro models (i.e. sgRNA against Slc1a5, cells from SLC1A5 conditional knockout mice, GPNA-treatment).</p><p>2. Based on the whole-skeleton stainings, the defect caused by SLC1A5 deletion appears to disappear in long bones of P0 mice. Is BV/TV decreased in long bones of SLC1A5 knockout mice, and, if so, does the bone phenotype progress in (young) adult mice? This is likely important information, as this would suggest that only a transient upregulation of SLC1A5 activity is required during bone development.</p><p>3. Is protein and matrix synthesis affected by GPNA treatment, thereby mimicking the genetic models?</p><p>4. The observation that asparagine depletion increases proliferation is interesting. Is glutamine uptake and/or catabolism increased in these conditions?</p><p>5. Figure 6A-F, Figure S5A-B â please provide statistics.</p><p>6. Please provide scale bars in Figure 1P-U, Figure S1Q-W, Figure S2A-W.</p><p>7. There appears to be some variation in the degree of mineralization in the different experiments (e.g. Figure S2Y), which might affect the effect size of the treatment condition.</p><p>8. For some experiments, the authors used the term 'ACTS2' instead of SLC1A5. It might be clearer to use SLC1A5 throughout.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>This work by Sharma et al., studied the role of aa transporter, ASCT2, encoded by Slc1a5 gene, that transports mostly Glmn and Asn, in osteoblasts (OB). They use gene targeting in vitro and in vivo using Sp7-Cre driven cKO. They found that ASCT2 deletion impairs OB differentiation in vitro as well as mostly intramembranous ossification in vivo by interfering with proliferation and protein synthesis. Mechanistically, they show that Glmn uptake via ASCT2 is important for aa synthesis in OBs.</p><p>This group has shown before that Glmn is essential for OB metabolism. The current work further investigates this phenomenon and identifies ASCT2 as the key mechanism of Glmn uptake into OBs.</p><p>The work is logically structured and carefully done with appropriate in vivo and in vitro controls. A variety of methods is used to confirm their findings, such as in vivo immunodetection and in situ hybridization and in vitro metabolic tracing. The conclusions are well justified by the data.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71595.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Reviewers all agree the study is interesting, but a series of critical issues were raised that need to be addressed by either performing additional experiments or clarifying their interpretation of the current results.</p><p>Please address concerns and comments point-by-point.</p><p>In particular, it is crucial to carefully discuss the novelty of the findings. In addition, it is critical to clarify whether the OSX-Cre driver used in the study is inducible.</p></disp-quote><p>We thank the editor and reviewers for their constructive comments that have given us the opportunity to improve this work. We can confirm the Sp7Cre driver (<italic>Sp7Cre;tTAtetOeGFP</italic>) we used in this study is inducible (DOX OFF) although we did not use it in this manner. We used this as a constitutive CRE line in this study. We have better described this Cre line and the controls we used in the methods. Also, we have expanded the discussion to include a new paragraph that better discusses the novelty of our findings. The relevant text is as follows:</p><p>âGlutamine is an essential nutrient in osteoblasts. We and others have shown that glutamine metabolism contribute to many downstream metabolites in osteoblasts including aKG, non-essential amino acids (NEAA) and the tripeptide antioxidant glutathione. These different studies have demonstrated these glutamine derived metabolites regulate distinct processes during osteoblast differentiation. For example, aKG is essential for skeletal stem cell proliferation, GSH regulates osteoblast viability while NEAA are important for differentiation. We have extended these previous findings by identifying SLC1A5 as the primary glutamine transporter in osteoblasts. SLC1A5 is responsible for a majority of glutamine uptake importing 53.5% of glutamine in osteoblasts. In addition, <italic>Slc1a5</italic> is a minor contributor to asparagine uptake importing 19.5% of asparagine in osteoblasts. Consistent with our own and others previous reports, we found glutamine is a critical nutrient at all stages of osteoblast differentiation whereas asparagine is more important for terminal osteoblast differentiation. To our knowledge this represents the first demonstration of the necessity of asparagine for osteoblast differentiation. Although it is likely that osteoblasts rely heavily on other transporters in addition to SLC1A5 to provide asparagine during differentiation.â</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Specific Comments:</p><p>1. The authors show that impairing the intracellular transport of glutamine and asparagine decreases the intracellular accumulation of metabolites of the TCA cycle such as citrate and Î±-ketoglutarate. Is mitochondrial respiration negatively affected in mutant osteoblasts? Are the mutant cells energy deficient?</p></disp-quote><p>We thank the reviewer for the overall positive review of our work. We have not evaluated mitochondrial respiration directly. In our initial characterization of these mice, we did not observe obvious changes in markers of energetic stress (e.g. increased pThr172 of AMPK). Because of this, we focused our analyses on amino acid homeostasis as this was obviously affected in the <italic>Slc1a5</italic> mutant cells.</p><disp-quote content-type="editor-comment"><p>2. Are the widening of the sutures and the delay of the osteogenic front still present in the flat bones of the skull in mutant mice postnatally?</p></disp-quote><p>The suture phenotype is present in postnatal stages. We have included X-Ray, ÂµCT and histology of 2-month-old <italic>Sp7Cre;Slc1a5<sup>fl/fl</sup></italic> mice. Increased suture width and altered suture morphology is evident at this age. We have included these data in Figure 1 âfigure supplement 2.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. The authors propose that inactivation of SLC1A5 affects osteoblast differentiation. While matrix mineralization is clearly decreased, it is not fully clear whether ALP staining is affected to the same extent using the different in vitro models (i.e. sgRNA against Slc1a5, cells from SLC1A5 conditional knockout mice, GPNA-treatment).</p></disp-quote><p>It is difficult to directly compare these experiments. One involves a chemical inhibitor (GPNA) while the other two are genetic in nature. Sp7Cre (which deletes Slc1a5 only in Sp7 expressing cells that already express ALPL) is not expressed in naÃ¯ve calvarial cells and only becomes expressed after osteogenic induction. The sgRNA experiment is targeting Slc1a5 in naÃ¯ve cells prior to ALPL and Sp7 expression. Likewise, GPNA is an acute inhibition targeting naÃ¯ve cells. All three models demonstrated a consistent inhibition of both matrix mineralization and the induction of terminal osteoblast marker genes like <italic>Ibsp</italic> and <italic>Bglap.</italic> Thus, we conclude Slc1a5 is essential for osteoblast differentiation.</p><disp-quote content-type="editor-comment"><p>2. Based on the whole-skeleton stainings, the defect caused by SLC1A5 deletion appears to disappear in long bones of P0 mice. Is BV/TV decreased in long bones of SLC1A5 knockout mice, and, if so, does the bone phenotype progress in (young) adult mice? This is likely important information, as this would suggest that only a transient upregulation of SLC1A5 activity is required during bone development.</p></disp-quote><p>We apologize for giving the impression that the phenotype only affected the calvarium and the long bones were normal at birth. We evaluated the long bone phenotypes in the Slc1a5 knockout mice at both birth (P0) and 2-months of age. At birth, these mice are characterized by reduced expression of late osteoblast genes <italic>Spp1</italic> and <italic>Bglap</italic> with no change in <italic>Col1a1</italic> as measured by qPCR from whole bone shafts and in situ hybridization. At 2-months of age, the knockout mice have significantly decreased trabecular BV/TV and decreased OCN positive cells. We have included these data in Figure 2 âfigure supplement 2.</p><disp-quote content-type="editor-comment"><p>3. Is protein and matrix synthesis affected by GPNA treatment, thereby mimicking the genetic models?</p></disp-quote><p>Yes, protein synthesis is significantly reduced in GPNA treated cells as determined by <sup>35</sup>S-Cys and Met incorporation. This data is included in Figure 2 âfigure supplement 1Y.</p><disp-quote content-type="editor-comment"><p>4. The observation that asparagine depletion increases proliferation is interesting. Is glutamine uptake and/or catabolism increased in these conditions?</p></disp-quote><p>The increase in proliferation when Asn is limiting was unexpected and we agree this finding is interesting. We have not evaluated either glutamine uptake or catabolism under these conditions. These are interesting experiments to perform in the future.</p><disp-quote content-type="editor-comment"><p>5. Figure 6A-F, Figure S5A-B â please provide statistics.</p></disp-quote><p>We have added statistics for these experiments.</p><disp-quote content-type="editor-comment"><p>6. Please provide scale bars in Figure 1P-U, Figure S1Q-W, Figure S2A-W.</p></disp-quote><p>We have added scale bars to these figures.</p><disp-quote content-type="editor-comment"><p>7. There appears to be some variation in the degree of mineralization in the different experiments (e.g. Figure S2Y), which might affect the effect size of the treatment condition.</p></disp-quote><p>We agree with the reviewer that the data in the original Figure S2Y is suboptimal. GPNA is dissolved in HCl, thus our vehicle control for those experiments is equal molar HCl. In our experience, this limits matrix mineralization under âcontrolâ conditions. Because the genetic data in Figures 1 and 2 is more robust we have removed the GPNA functional differentiation data.</p><disp-quote content-type="editor-comment"><p>8. For some experiments, the authors used the term 'ACTS2' instead of SLC1A5. It might be clearer to use SLC1A5 throughout.</p></disp-quote><p>Thank you for this suggestion. We have removed the references to ASCT2 and replaced them with SLC1A5.</p></body></sub-article></article>